<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Glaucoma in the Developing World - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAVjVpMvONnu5cW@mQ2EUgAAAAI","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Glaucoma_in_the_Developing_World","wgTitle":"Glaucoma in the Developing World","wgCurRevisionId":69913,"wgRevisionId":69913,"wgArticleId":3580,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles","Glaucoma"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Glaucoma_in_the_Developing_World","wgRelevantArticleId":3580,"wgIsProbablyEditable":!1,"wgRelevantPageIsProbablyEditable":!1,"wgRestrictionEdit":[],"wgRestrictionMove":[
],"sdgDownArrowImage":"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"srfFilteredConfig":null,
"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eyeWiki","ext.eyeWiki.slideshow","sentry.init","ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Overview of glaucoma in developing countries, including epidemiology, diagnosis, treatment, and future directives."/>
<meta name="date" content="2020-11-21"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Glaucoma in the Developing World" href="/w/index.php?title=Special:ExportRDF/Glaucoma_in_the_Developing_World&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Glaucoma_in_the_Developing_World rootpage-Glaucoma_in_the_Developing_World layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Glaucoma+in+the+Developing+World" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Glaucoma+in+the+Developing+World" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbpzyxntgc"></button>
					<div class="collapse navbar-collapse hbpzyxntgc" id="hbpzyxntgc">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Glaucoma_in_the_Developing_World" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk" class="new"><a href="/w/index.php?title=Talk:Glaucoma_in_the_Developing_World&amp;action=edit&amp;redlink=1" rel="discussion" title="Discussion about the content page (page does not exist) [t]" accesskey="t" class="new ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Glaucoma_in_the_Developing_World&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Glaucoma_in_the_Developing_World&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Glaucoma_in_the_Developing_World&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Glaucoma_in_the_Developing_World#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Glaucoma in the Developing World</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:David.Rooney" title="User:David.Rooney">David M. Rooney, MD</a>,&#8201;<a href="/User:Gagan.Kalra" title="User:Gagan.Kalra">Gagan Kalra, MD</a>,&#8201;<a href="/w/index.php?title=User:Geoffrey_Tabin&amp;action=formedit&amp;redlink=1" class="new" title="User:Geoffrey Tabin (page does not exist)">Geoffrey Tabin</a>,&#8201;<a href="/w/index.php?title=User:MD&amp;action=formedit&amp;redlink=1" class="new" title="User:MD (page does not exist)">MD</a>,&#8201;<a href="/w/index.php?title=User:Srinivasan_Kavitha&amp;action=formedit&amp;redlink=1" class="new" title="User:Srinivasan Kavitha (page does not exist)">Srinivasan Kavitha</a>,&#8201;<a href="/w/index.php?title=User:MD&amp;action=formedit&amp;redlink=1" class="new" title="User:MD (page does not exist)">MD</a>,&#8201;<a href="/w/index.php?title=User:Rengaraj_Venkatesh&amp;action=formedit&amp;redlink=1" class="new" title="User:Rengaraj Venkatesh (page does not exist)">Rengaraj Venkatesh</a>,&#8201;<a href="/w/index.php?title=User:MD&amp;action=formedit&amp;redlink=1" class="new" title="User:MD (page does not exist)">MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a>,&#160;<a href="/User:Daniel.B.Moore" title="User:Daniel.B.Moore">Daniel B. Moore, MD</a>,&#160;<a href="/User:Ian.Conner" title="User:Ian.Conner">Ian Conner, MD, PhD</a>,&#160;<a href="/User:David.Rooney" title="User:David.Rooney">David M. Rooney, MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Ian.Conner" title="User:Ian.Conner">Ian Conner, MD, PhD</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Update Pending</b>
</div>
</div>&#160;by <a href="/User:Ian.Conner" title="User:Ian.Conner">Ian Conner, MD, PhD</a> on November 22, 2020.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Glaucoma_in_the_Developing_World&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Glaucoma_in_the_Developing_World&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table> </div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Introduction"><span class="tocnumber">1</span> <span class="toctext">Introduction</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Epidemiology"><span class="tocnumber">2</span> <span class="toctext">Epidemiology</span></a>
<ul>
<li class="toclevel-2 tocsection-3"><a href="#Figure_1:_Prevalence_of_MSVI_and_blindness_due_to_glaucoma.5B16.5D_.5B17.5D_.5B18.5D_.5B19.5D_.5B20.5D_.5B21.5D"><span class="tocnumber">2.1</span> <span class="toctext">Figure 1: Prevalence of MSVI and blindness due to glaucoma<sup>&#91;16&#93;</sup> <sup>&#91;17&#93;</sup> <sup>&#91;18&#93;</sup> <sup>&#91;19&#93;</sup> <sup>&#91;20&#93;</sup> <sup>&#91;21&#93;</sup></span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#Figure_2:_Glaucoma_blindness_as_a_percentage_of_all_causes_of_blindness_in_each_country.5B16.5D_.5B17.5D_.5B18.5D_.5B19.5D_.5B20.5D_.5B21.5D"><span class="tocnumber">2.2</span> <span class="toctext">Figure 2: Glaucoma blindness as a percentage of all causes of blindness in each country<sup>&#91;16&#93;</sup> <sup>&#91;17&#93;</sup> <sup>&#91;18&#93;</sup> <sup>&#91;19&#93;</sup> <sup>&#91;20&#93;</sup> <sup>&#91;21&#93;</sup></span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#Primary_open-angle_glaucoma"><span class="tocnumber">2.3</span> <span class="toctext">Primary open-angle glaucoma</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#Primary_angle-closure_glaucoma"><span class="tocnumber">2.4</span> <span class="toctext">Primary angle-closure glaucoma</span></a></li>
<li class="toclevel-2 tocsection-7"><a href="#Childhood_glaucomas"><span class="tocnumber">2.5</span> <span class="toctext">Childhood glaucomas</span></a></li>
<li class="toclevel-2 tocsection-8"><a href="#Secondary_glaucomas"><span class="tocnumber">2.6</span> <span class="toctext">Secondary glaucomas</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-9"><a href="#Psychosocial_and_economic_impact"><span class="tocnumber">3</span> <span class="toctext">Psychosocial and economic impact</span></a></li>
<li class="toclevel-1 tocsection-10"><a href="#Glaucoma_management_and_its_challenges"><span class="tocnumber">4</span> <span class="toctext">Glaucoma management and its challenges</span></a>
<ul>
<li class="toclevel-2 tocsection-11"><a href="#Diagnosis"><span class="tocnumber">4.1</span> <span class="toctext">Diagnosis</span></a></li>
<li class="toclevel-2 tocsection-12"><a href="#Medical_management"><span class="tocnumber">4.2</span> <span class="toctext">Medical management</span></a></li>
<li class="toclevel-2 tocsection-13"><a href="#Surgery"><span class="tocnumber">4.3</span> <span class="toctext">Surgery</span></a></li>
<li class="toclevel-2 tocsection-14"><a href="#Lasers"><span class="tocnumber">4.4</span> <span class="toctext">Lasers</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-15"><a href="#Potential_solutions_and_future_directives"><span class="tocnumber">5</span> <span class="toctext">Potential solutions and future directives</span></a>
<ul>
<li class="toclevel-2 tocsection-16"><a href="#Diagnosis_2"><span class="tocnumber">5.1</span> <span class="toctext">Diagnosis</span></a></li>
<li class="toclevel-2 tocsection-17"><a href="#Teleglaucoma"><span class="tocnumber">5.2</span> <span class="toctext">Teleglaucoma</span></a>
<ul>
<li class="toclevel-3 tocsection-18"><a href="#Smartphone-based_testing"><span class="tocnumber">5.2.1</span> <span class="toctext">Smartphone-based testing</span></a></li>
<li class="toclevel-3 tocsection-19"><a href="#Artifical_intelligence_.28AI.29_and_deep_learning"><span class="tocnumber">5.2.2</span> <span class="toctext">Artifical intelligence (AI) and deep learning</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-20"><a href="#Patient_education_and_awareness"><span class="tocnumber">5.3</span> <span class="toctext">Patient education and awareness</span></a></li>
<li class="toclevel-2 tocsection-21"><a href="#Medical_management_2"><span class="tocnumber">5.4</span> <span class="toctext">Medical management</span></a></li>
<li class="toclevel-2 tocsection-22"><a href="#Eye_care_professional_education"><span class="tocnumber">5.5</span> <span class="toctext">Eye care professional education</span></a></li>
<li class="toclevel-2 tocsection-23"><a href="#Eye_care_integration_into_existing_systems"><span class="tocnumber">5.6</span> <span class="toctext">Eye care integration into existing systems</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-24"><a href="#Conclusion"><span class="tocnumber">6</span> <span class="toctext">Conclusion</span></a></li>
<li class="toclevel-1 tocsection-25"><a href="#Additional_Resources"><span class="tocnumber">7</span> <span class="toctext">Additional Resources</span></a></li>
<li class="toclevel-1 tocsection-26"><a href="#References"><span class="tocnumber">8</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h1><span class="mw-headline" id="Introduction">Introduction</span></h1>
<p>Glaucoma is the most common cause of irreversible vision loss and the third most common cause of vision loss worldwide after cataracts and refractive error.<sup id="cite_ref-:0_1-0" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup> <sup id="cite_ref-:1_2-0" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup> In developing countries, those afflicted with the disease are at a particular disadvantage in comparison to persons with glaucoma in developed nations; they have a higher incidence of disease, more advanced disease at presentation, and a higher risk of progressing to blindness.<sup id="cite_ref-3" class="reference"><a href="#cite_note-3">&#91;3&#93;</a></sup> <sup id="cite_ref-4" class="reference"><a href="#cite_note-4">&#91;4&#93;</a></sup> Glaucoma prevention and treatment has been a major focus of international directives, including the World Health Organization’s Vision 2020 campaign. While this initiative saw a successful decrease in worldwide blindness, most of the improvement was due to widespread adoption of cataract surgery and spectacles provision. Stated goals regarding number of ophthalmologists and optometrists in developing nations remain unfulfilled.<sup id="cite_ref-5" class="reference"><a href="#cite_note-5">&#91;5&#93;</a></sup> <sup id="cite_ref-6" class="reference"><a href="#cite_note-6">&#91;6&#93;</a></sup> <sup id="cite_ref-7" class="reference"><a href="#cite_note-7">&#91;7&#93;</a></sup>
</p><p>There are several unique challenges to addressing glaucoma in the developing world. Glaucoma is difficult to diagnose in any context; it is almost always asymptomatic until late in the disease course. This painless, insidious vision loss results in late diagnosis unless patients are screened for glaucoma early on. Access to eye care in developing countries remains a major issue, particularly in rural areas. Most ophthalmologists are concentrated in urban areas, leaving many people in resource-limited countries unable to obtain the regular eye exams and glaucoma treatment necessary to prevent permanent vision loss. Understanding or even awareness of glaucoma is virtually nonexistent in some populations, leading to unrealistic expectations of vision restoration through surgery.<sup id="cite_ref-:15_8-0" class="reference"><a href="#cite_note-:15-8">&#91;8&#93;</a></sup> While this type of surgical outcome is attainable with reversible causes of vision loss such as cataracts, it is impossible for patients with advanced glaucoma to regain functional vision. This misunderstanding is prevalent across the developing world and is only one symptom of a widespread lack of education regarding eye health.<sup id="cite_ref-9" class="reference"><a href="#cite_note-9">&#91;9&#93;</a></sup> <sup id="cite_ref-10" class="reference"><a href="#cite_note-10">&#91;10&#93;</a></sup> Misinformation regarding eye diseases and treatment options also discourages many from seeking any eye care at all.<sup id="cite_ref-11" class="reference"><a href="#cite_note-11">&#91;11&#93;</a></sup>
</p><p>In resource-limited countries, glaucoma care providers tend to favor a more aggressive treatment approach than that of developed countries. Reliable follow-up is less likely and patients are often unable to obtain or afford medications. Consequently, incisional glaucoma surgery typically is first-line treatment, instead of being reserved for those who fail medical management.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12">&#91;12&#93;</a></sup> <sup id="cite_ref-:16_13-0" class="reference"><a href="#cite_note-:16-13">&#91;13&#93;</a></sup>
</p><p>The majority of glaucoma data are collected from European and North American studies. Information from the developing world is limited, but has increased in recent years. This article examines the state of glaucoma in the developing world, with particular attention given to epidemiology, approach to treatment, and outlook for the future.
</p>
<h1><span class="mw-headline" id="Epidemiology">Epidemiology</span></h1>
<p>The prevalence of glaucoma in developing countries is difficult to pinpoint because of differences in defining glaucoma, variable expertise of diagnosticians, and frequent unavailability of necessary diagnostic equipment. Much of the available epidemiology likely underestimates the true glaucoma burden in developing countries due to reliance on visual acuity thresholds for diagnosing glaucoma.<sup id="cite_ref-:17_14-0" class="reference"><a href="#cite_note-:17-14">&#91;14&#93;</a></sup> The estimated number of people with glaucoma worldwide is expected to rise from 76 million in 2020 to 111 million in 2040, with Africa and Asia being affected more heavily than the rest of the world.<sup id="cite_ref-:1_2-1" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup> <sup id="cite_ref-:2_15-0" class="reference"><a href="#cite_note-:2-15">&#91;15&#93;</a></sup> The total amount of glaucoma care has increased worldwide in recent years, but rapid growth in the global population coupled with demographic shifts toward older populations has limited the impact of this expansion of care on a global per capita basis.<sup id="cite_ref-:0_1-1" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup>
</p>
<h3><span id="Figure_1:_Prevalence_of_MSVI_and_blindness_due_to_glaucoma[16]_[17]_[18]_[19]_[20]_[21]"></span><span class="mw-headline" id="Figure_1:_Prevalence_of_MSVI_and_blindness_due_to_glaucoma.5B16.5D_.5B17.5D_.5B18.5D_.5B19.5D_.5B20.5D_.5B21.5D">Figure 1: Prevalence of MSVI and blindness due to glaucoma<sup id="cite_ref-:3_16-0" class="reference"><a href="#cite_note-:3-16">&#91;16&#93;</a></sup> <sup id="cite_ref-:4_17-0" class="reference"><a href="#cite_note-:4-17">&#91;17&#93;</a></sup> <sup id="cite_ref-:5_18-0" class="reference"><a href="#cite_note-:5-18">&#91;18&#93;</a></sup> <sup id="cite_ref-:6_19-0" class="reference"><a href="#cite_note-:6-19">&#91;19&#93;</a></sup> <sup id="cite_ref-:7_20-0" class="reference"><a href="#cite_note-:7-20">&#91;20&#93;</a></sup> <sup id="cite_ref-:8_21-0" class="reference"><a href="#cite_note-:8-21">&#91;21&#93;</a></sup></span></h3>
<div class="thumb tleft"><div class="thumbinner" style="width:1127px;"><a href="/File:Glaucoma_MSVI_Blindness2.png" class="image"><img alt="" src="/w/images/1/thumb/1/19/Glaucoma_MSVI_Blindness2.png/1125px-Glaucoma_MSVI_Blindness2.png" decoding="async" width="1125" height="501" class="thumbimage" srcset="/w/images/1/thumb/1/19/Glaucoma_MSVI_Blindness2.png/1688px-Glaucoma_MSVI_Blindness2.png 1.5x, /w/images/1/thumb/1/19/Glaucoma_MSVI_Blindness2.png/2250px-Glaucoma_MSVI_Blindness2.png 2x" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/File:Glaucoma_MSVI_Blindness2.png" class="internal" title="Enlarge"></a></div><b>Figure 1</b>: Estimated regional prevalence of moderate and severe visual impairment (MSVI) and blindness due to glaucoma in 2020. MSVI is defined as visual acuity &lt; 6/18 but ≥3/60 in the better seeing eye and blindness is defined as &lt;3/60 in the better seeing eye. Adapted from contemporary prevalence studies.<sup>16-21</sup></div></div></div>  
<p><br clear="all" />
</p>
<h3><span id="Figure_2:_Glaucoma_blindness_as_a_percentage_of_all_causes_of_blindness_in_each_country[16]_[17]_[18]_[19]_[20]_[21]"></span><span class="mw-headline" id="Figure_2:_Glaucoma_blindness_as_a_percentage_of_all_causes_of_blindness_in_each_country.5B16.5D_.5B17.5D_.5B18.5D_.5B19.5D_.5B20.5D_.5B21.5D">Figure 2: Glaucoma blindness as a percentage of all causes of blindness in each country<sup id="cite_ref-:3_16-1" class="reference"><a href="#cite_note-:3-16">&#91;16&#93;</a></sup> <sup id="cite_ref-:4_17-1" class="reference"><a href="#cite_note-:4-17">&#91;17&#93;</a></sup> <sup id="cite_ref-:5_18-1" class="reference"><a href="#cite_note-:5-18">&#91;18&#93;</a></sup> <sup id="cite_ref-:6_19-1" class="reference"><a href="#cite_note-:6-19">&#91;19&#93;</a></sup> <sup id="cite_ref-:7_20-1" class="reference"><a href="#cite_note-:7-20">&#91;20&#93;</a></sup> <sup id="cite_ref-:8_21-1" class="reference"><a href="#cite_note-:8-21">&#91;21&#93;</a></sup></span></h3>
<div class="thumb tnone"><div class="thumbinner" style="width:1127px;"><a href="/File:Glaucoma_blindness_percentage_of_all2.jpg" class="image"><img alt="" src="/w/images/1/thumb/4/46/Glaucoma_blindness_percentage_of_all2.jpg/1125px-Glaucoma_blindness_percentage_of_all2.jpg" decoding="async" width="1125" height="445" class="thumbimage" srcset="/w/images/1/thumb/4/46/Glaucoma_blindness_percentage_of_all2.jpg/1688px-Glaucoma_blindness_percentage_of_all2.jpg 1.5x, /w/images/1/thumb/4/46/Glaucoma_blindness_percentage_of_all2.jpg/2250px-Glaucoma_blindness_percentage_of_all2.jpg 2x" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/File:Glaucoma_blindness_percentage_of_all2.jpg" class="internal" title="Enlarge"></a></div><b>Figure 2</b>: Estimated percentage of the total burden of blindness due to glaucoma by country in 2020. blindness is defined as &lt;3/60 in the better seeing eye. Data adapted from contemporary prevalence studies.<sup>16-21</sup></div></div></div>
<h3><span class="mw-headline" id="Primary_open-angle_glaucoma">Primary open-angle glaucoma</span></h3>
<p>Primary open-angle glaucoma (POAG) is the most common form of the disease worldwide. The highest prevalence of POAG is in African countries and in communities of African descent, such as African American and Afro-Caribbean populations.<sup id="cite_ref-:2_15-1" class="reference"><a href="#cite_note-:2-15">&#91;15&#93;</a></sup> <sup id="cite_ref-:9_22-0" class="reference"><a href="#cite_note-:9-22">&#91;22&#93;</a></sup> <sup id="cite_ref-23" class="reference"><a href="#cite_note-23">&#91;23&#93;</a></sup> A 2014 review of worldwide POAG prevalence among people aged 40-80 years showed estimates of 2.31% in Asia, 3.65% in Latin America and the Caribbean, and 4.20% in Africa.<sup id="cite_ref-:2_15-2" class="reference"><a href="#cite_note-:2-15">&#91;15&#93;</a></sup> Another study based in West Africa showed a POAG prevalence of nearly 15% in individuals over the age of 80.<sup id="cite_ref-:9_22-1" class="reference"><a href="#cite_note-:9-22">&#91;22&#93;</a></sup> Among Asian populations, the prevalence of POAG ranges from 0.5% in a Mongolian population to 3.9% in a Japanese population.<sup id="cite_ref-:10_24-0" class="reference"><a href="#cite_note-:10-24">&#91;24&#93;</a></sup> <sup id="cite_ref-25" class="reference"><a href="#cite_note-25">&#91;25&#93;</a></sup> <sup id="cite_ref-26" class="reference"><a href="#cite_note-26">&#91;26&#93;</a></sup>
</p><p>Although several genetic loci have been identified as “glaucoma genes”, inheritance of POAG is usually multigenic and multifactorial, having no identified association with a particular gene in most populations. Environmental factors and modifying genes likely play a role in disease development.<sup id="cite_ref-27" class="reference"><a href="#cite_note-27">&#91;27&#93;</a></sup> <sup id="cite_ref-28" class="reference"><a href="#cite_note-28">&#91;28&#93;</a></sup> <sup id="cite_ref-29" class="reference"><a href="#cite_note-29">&#91;29&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Primary_angle-closure_glaucoma">Primary angle-closure glaucoma</span></h3>
<p>Angle-closure glaucoma is the second most common form of the disease. Primary angle-closure glaucoma (PACG) is responsible for nearly half the glaucoma-related blindness in the world, despite being much less common than POAG. Asia bears the greatest burden of PACG with reported prevalence reaching as high as 2.5% in Myanmar.<sup id="cite_ref-:10_24-1" class="reference"><a href="#cite_note-:10-24">&#91;24&#93;</a></sup> <sup id="cite_ref-30" class="reference"><a href="#cite_note-30">&#91;30&#93;</a></sup> Females are more likely to have PACG, with a 1.5:1 female to male ratio observed in Asians.<sup id="cite_ref-:11_31-0" class="reference"><a href="#cite_note-:11-31">&#91;31&#93;</a></sup> Angle closure disease is much less common outside of Asia.
</p><p>Family history has been identified as a major risk factor for development of angle-closure glaucoma. In an Iranian study, 58% of siblings of patients with angle closure glaucoma were found to have some degree of angle closure.<sup id="cite_ref-32" class="reference"><a href="#cite_note-32">&#91;32&#93;</a></sup> Findings from this study are consistent with previous PACG studies from India and Singapore, in which 50% and 59% of siblings were affected, respectively.<sup id="cite_ref-33" class="reference"><a href="#cite_note-33">&#91;33&#93;</a></sup> <sup id="cite_ref-34" class="reference"><a href="#cite_note-34">&#91;34&#93;</a></sup> <sup id="cite_ref-35" class="reference"><a href="#cite_note-35">&#91;35&#93;</a></sup> It has long been established that angle closure is more common in Asian populations. However, there are only a few studies differentiating between ethnic groups living in a single area.<sup id="cite_ref-:11_31-1" class="reference"><a href="#cite_note-:11-31">&#91;31&#93;</a></sup> <sup id="cite_ref-36" class="reference"><a href="#cite_note-36">&#91;36&#93;</a></sup> <sup id="cite_ref-37" class="reference"><a href="#cite_note-37">&#91;37&#93;</a></sup> &#160;A study evaluating the course of angle closure glaucoma in different ethnic groups living in Malaysia found that Malays presented to clinic with higher intraocular pressures (IOPs), worse vision, more advanced optic disc changes, and at an older age than Chinese living in Malaysia. The Malay group also experienced faster glaucoma progression than the Chinese group.<sup id="cite_ref-38" class="reference"><a href="#cite_note-38">&#91;38&#93;</a></sup> <sup id="cite_ref-39" class="reference"><a href="#cite_note-39">&#91;39&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Childhood_glaucomas">Childhood glaucomas</span></h3>
<p>	Childhood blindness is a much larger problem in the developing world than in the developed world. About three-quarters of the world’s blind children live in impoverished areas of Africa and Asia alone.<sup id="cite_ref-:12_40-0" class="reference"><a href="#cite_note-:12-40">&#91;40&#93;</a></sup> Poorer countries are also more likely to have a larger percentage of blindness in children due to avoidable causes.<sup id="cite_ref-:12_40-1" class="reference"><a href="#cite_note-:12-40">&#91;40&#93;</a></sup> In a study conducted in Ghana, Honduras, and India, 95% of caregivers believed that it was important for children to have eye exams, but 66% had never undergone one.<sup id="cite_ref-:13_41-0" class="reference"><a href="#cite_note-:13-41">&#91;41&#93;</a></sup> Accordingly, the prevention and treatment of diseases that cause blindness during childhood are of particular concern to the WHO. The concept of blind years also highlights the importance of addressing childhood blindness; despite its relative rarity, the total number of blind years due to childhood blindness is almost equal to the number of blind years due to adult cataracts.<sup id="cite_ref-:12_40-2" class="reference"><a href="#cite_note-:12-40">&#91;40&#93;</a></sup>
</p><p>The most common type of infantile glaucoma in the world is primary congenital glaucoma (PCG), although it is still rare with an incidence of about 1 in 10,000 to 18,000 live births. Significantly higher PCG prevalence has been reported in populations where consanguineous relationships are common.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42">&#91;42&#93;</a></sup> <sup id="cite_ref-:14_43-0" class="reference"><a href="#cite_note-:14-43">&#91;43&#93;</a></sup> <sup id="cite_ref-44" class="reference"><a href="#cite_note-44">&#91;44&#93;</a></sup> Late diagnosis and advanced disease at presentation are common. One study from Ethiopia found the mean age at diagnosis of PCG to be 3.3 years.<sup id="cite_ref-45" class="reference"><a href="#cite_note-45">&#91;45&#93;</a></sup> This is in contrast to the developed world, where the diagnosis is almost always made within the first year of life.<sup id="cite_ref-:14_43-1" class="reference"><a href="#cite_note-:14-43">&#91;43&#93;</a></sup> <sup id="cite_ref-46" class="reference"><a href="#cite_note-46">&#91;46&#93;</a></sup> In this Ethiopian case series, the authors suspected a poor long-term prognosis for their patients despite appropriate surgical intervention because of inadequate follow-up and unavailability of medications.
</p><p>Post-cataract surgery glaucoma is another type of childhood glaucoma that is particularly important in developing nations. Due to the relatively large number of cataract operations performed in a medical mission setting, long-term follow-up to assess for complications is often not feasible. As pediatric cataract surgery rates increase, there is an increasing incidence of related secondary glaucoma. A study conducted at a Tanzanian tertiary pediatric eye center found a 6.5% risk for glaucoma at three years post cataract extraction in children under age 18.<sup id="cite_ref-47" class="reference"><a href="#cite_note-47">&#91;47&#93;</a></sup> Previous studies have reported significantly higher rates of glaucoma development when children are followed for longer time periods after surgery.<sup id="cite_ref-:13_41-1" class="reference"><a href="#cite_note-:13-41">&#91;41&#93;</a></sup> <sup id="cite_ref-48" class="reference"><a href="#cite_note-48">&#91;48&#93;</a></sup> <sup id="cite_ref-49" class="reference"><a href="#cite_note-49">&#91;49&#93;</a></sup> <sup id="cite_ref-50" class="reference"><a href="#cite_note-50">&#91;50&#93;</a></sup> <sup id="cite_ref-51" class="reference"><a href="#cite_note-51">&#91;51&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Secondary_glaucomas">Secondary glaucomas</span></h3>
<p>Lens-induced glaucoma (LIG) is the most common form of secondary glaucoma in many resource-limited countries. For example, LIG accounted for 5.3% of all causes of glaucoma presenting to a tertiary eye hospital in Nepal between 2007 and 2008.<sup id="cite_ref-52" class="reference"><a href="#cite_note-52">&#91;52&#93;</a></sup> This relatively high prevalence is a reflection of the large backlog of advanced cataracts in the developing world.
</p><p>Other secondary forms of glaucoma such as neovascular and pseudoexfoliative glaucoma have not been studied widely in developing countries. A Nigerian population-based study identified a 0.9% prevalence of all forms of secondary glaucoma. Of those patients diagnosed with neovascular glaucoma, 84% of affected eyes were blind on presentation. The study also identified a 0.2% prevalence of non-neovascular open-angle glaucoma secondary to couching, which is the same prevalence of neovascular cases in the study population. This finding reflects the reality that cataract surgery by couching is still a surprisingly common practice in some developing countries, despite a similar cost and vastly inferior outcomes compared to extracapsular cataract extraction.<sup id="cite_ref-53" class="reference"><a href="#cite_note-53">&#91;53&#93;</a></sup> <sup id="cite_ref-54" class="reference"><a href="#cite_note-54">&#91;54&#93;</a></sup> <sup id="cite_ref-55" class="reference"><a href="#cite_note-55">&#91;55&#93;</a></sup> <sup id="cite_ref-56" class="reference"><a href="#cite_note-56">&#91;56&#93;</a></sup> <sup id="cite_ref-57" class="reference"><a href="#cite_note-57">&#91;57&#93;</a></sup> Diabetes mellitus, which is a major cause of neovascular glaucoma in the developed world, was found in only 8.3% of subjects, while 62% had systemic hypertension.<sup id="cite_ref-58" class="reference"><a href="#cite_note-58">&#91;58&#93;</a></sup> <sup id="cite_ref-59" class="reference"><a href="#cite_note-59">&#91;59&#93;</a></sup> <sup id="cite_ref-60" class="reference"><a href="#cite_note-60">&#91;60&#93;</a></sup> A study on neovascular glaucoma conducted in Saudi Arabia found the most common cause of the disease to be diabetic retinopathy, followed by retinal vein obstruction. A history of diabetes was reported in 65% of subjects. Less common causes included chronic retinal detachment, carotid artery stenosis, retinoblastoma, and uveitis.<sup id="cite_ref-61" class="reference"><a href="#cite_note-61">&#91;61&#93;</a></sup>
</p><p>In a tertiary eye care center in India, common causes of secondary glaucoma included vitrectomy surgery (14%), trauma (13%), corneal pathology (12%), aphakia (11%), neovascular glaucoma (10%), pseudophakia (10%), steroid-induced glaucoma (8%), uveitic glaucoma (8%), and miscellaneous causes (14%). When grouped by patient age, the most common type of secondary glaucoma for 0-20 years of age was trauma; post-vitreoretinal surgery for 21-40 years of age; neovascular glaucoma for 41-60 years of age; and pseudophakic glaucoma for those over 60 years of age.<sup id="cite_ref-62" class="reference"><a href="#cite_note-62">&#91;62&#93;</a></sup>
</p><p>Pseudoexfoliative glaucoma is a relatively uncommon form of secondary glaucoma in most regions of the developing world. However, one clinic in Ethiopia has reported it as the most common subtype of glaucoma, identified in 35% of glaucoma patients.<sup id="cite_ref-63" class="reference"><a href="#cite_note-63">&#91;63&#93;</a></sup> In a South Indian population study, pseudoexfoliation was identified in 3.7% of subjects, and of these 8.3% had associated glaucoma.<sup id="cite_ref-64" class="reference"><a href="#cite_note-64">&#91;64&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Psychosocial_and_economic_impact">Psychosocial and economic impact</span></h1>
<p>Poor health is strongly associated with low socioeconomic status in the developing world, and eye disease is no exception.<sup id="cite_ref-:18_65-0" class="reference"><a href="#cite_note-:18-65">&#91;65&#93;</a></sup> <sup id="cite_ref-66" class="reference"><a href="#cite_note-66">&#91;66&#93;</a></sup> Glaucoma specifically can have a potentially devastating impact on quality of life, and glaucoma’s irreversible of vision loss makes early diagnosis and treatment all the more critical. On a quality of life scale from 0 to 1, where 0 represents death and 1 represents perfect health, an Indian population with glaucoma reported a mean utility value of 0.64, much lower than the score reported a similar study in U.S. citizens with glaucoma. Brazilians with glaucoma also report a range of utility values lower than their U.S. counterparts. This suggests persons with glaucoma in developing countries feel a stronger impact on their quality of life.<sup id="cite_ref-67" class="reference"><a href="#cite_note-67">&#91;67&#93;</a></sup> <sup id="cite_ref-68" class="reference"><a href="#cite_note-68">&#91;68&#93;</a></sup> Not surprisingly, the degree of impact on quality of life is closely correlated with degree of visual impairment across all areas of the developing world.<sup id="cite_ref-69" class="reference"><a href="#cite_note-69">&#91;69&#93;</a></sup> <sup id="cite_ref-70" class="reference"><a href="#cite_note-70">&#91;70&#93;</a></sup> <sup id="cite_ref-71" class="reference"><a href="#cite_note-71">&#91;71&#93;</a></sup>
</p><p>An often-overlooked effect of blindness is the secondary impact on those around a given blind person. Caregivers of vision impaired persons often bear a significant burden related to financial stress, low education, and being forced to become a caregiver.<sup id="cite_ref-72" class="reference"><a href="#cite_note-72">&#91;72&#93;</a></sup> A study in India reported an increased prevalence of depression in caregivers of persons with low vision or blindness. The rate of caregiver depression increased from 16% in the 20/200 group to 48% in the no light perception group. Low income was also associated with higher rates of depression.<sup id="cite_ref-73" class="reference"><a href="#cite_note-73">&#91;73&#93;</a></sup>
</p><p>Blindness often removes two people from the workforce: the blind patient, and a family member to care for the patient.<sup id="cite_ref-:18_65-1" class="reference"><a href="#cite_note-:18-65">&#91;65&#93;</a></sup> Thus, glaucoma’s impact spreads far beyond individuals and their families; vision impairment and blindness have a major impact on local and national economies.<sup id="cite_ref-74" class="reference"><a href="#cite_note-74">&#91;74&#93;</a></sup> <sup id="cite_ref-75" class="reference"><a href="#cite_note-75">&#91;75&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Glaucoma_management_and_its_challenges">Glaucoma management and its challenges</span></h1>
<h3><span class="mw-headline" id="Diagnosis">Diagnosis</span></h3>
<p>Universal community screening for glaucoma in developing countries is not economically feasible due to the limited numbers of providers capable of performing screenings, as well as financial and transportation barriers.<sup id="cite_ref-76" class="reference"><a href="#cite_note-76">&#91;76&#93;</a></sup> <sup id="cite_ref-:19_77-0" class="reference"><a href="#cite_note-:19-77">&#91;77&#93;</a></sup> <sup id="cite_ref-:20_78-0" class="reference"><a href="#cite_note-:20-78">&#91;78&#93;</a></sup> Many patients initially present when they become symptomatic from glaucoma or another ophthalmic issue. Consequently, late diagnosis is much more common in resource-limited countries.<sup id="cite_ref-:21_79-0" class="reference"><a href="#cite_note-:21-79">&#91;79&#93;</a></sup> For example, a study conducted in a rural population in northeastern Ghana showed bilateral blindness in 34% and unilateral blindness in half of patients receiving an initial glaucoma diagnosis.<sup id="cite_ref-80" class="reference"><a href="#cite_note-80">&#91;80&#93;</a></sup> This is in line with several other studies in Sub-Saharan Africa, which report a unilateral blindness rate of up to 56% in newly diagnosed glaucoma patients.<sup id="cite_ref-:22_81-0" class="reference"><a href="#cite_note-:22-81">&#91;81&#93;</a></sup>
</p><p>Due to limited diagnostic resources, diagnosis is often made based on IOP, vision, and examination without any ancillary testing such as formal visual fields and OCTs. One recent survey of Nigerian glaucoma management found that basic diagnostic equipment was unavailable in 15-20% of clinics.<sup id="cite_ref-82" class="reference"><a href="#cite_note-82">&#91;82&#93;</a></sup> Gonioscopy is not always feasible at the point of screening due to a lack of access to the necessary equipment and/or personnel trained at performing gonioscopy. Thus, the use of van Herick grading or even oblique flashlight grading is more often utilized in screening for occludable angles.<sup id="cite_ref-:20_78-1" class="reference"><a href="#cite_note-:20-78">&#91;78&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Medical_management">Medical management</span></h3>
<p>Medical management of glaucoma in developing countries is more difficult than in developed countries due to more advanced disease at time of presentation, limited access to ophthalmic medications, lack of affordability of medications, variable quality of generic ophthalmics, and poor follow-up.<sup id="cite_ref-:23_83-0" class="reference"><a href="#cite_note-:23-83">&#91;83&#93;</a></sup> <sup id="cite_ref-:24_84-0" class="reference"><a href="#cite_note-:24-84">&#91;84&#93;</a></sup> <sup id="cite_ref-85" class="reference"><a href="#cite_note-85">&#91;85&#93;</a></sup> A study from India highlighted the significant economic burden caused by anti-glaucoma drug regimens, particularly on poorer people from rural areas. The monthly cost of glaucoma medications represented 13%-123% of monthly income for the patients in the lowest socioeconomic groups. This did not take into account the lost income or costs of travel for their appointments, which are often greater than the cost of the medicine itself. The vast majority did not have any type of insurance or reimbursement for costs of treatment.<sup id="cite_ref-86" class="reference"><a href="#cite_note-86">&#91;86&#93;</a></sup> As such, glaucoma medical management in the developing world typically is reserved for patients with early glaucoma whose medication adherence and follow-up are all but certain or for patients who decline surgery.
</p>
<h3><span class="mw-headline" id="Surgery">Surgery</span></h3>
<p>Surgery is generally regarded as the preferred first-line treatment for glaucoma in developing countries.<sup id="cite_ref-87" class="reference"><a href="#cite_note-87">&#91;87&#93;</a></sup> <sup id="cite_ref-:25_88-0" class="reference"><a href="#cite_note-:25-88">&#91;88&#93;</a></sup> <sup id="cite_ref-:26_89-0" class="reference"><a href="#cite_note-:26-89">&#91;89&#93;</a></sup> This is due to late diagnosis, poor follow-up, and the aforementioned difficulties of medical management. Small prospective trials of early glaucoma surgery in developing countries have demonstrated favorable outcomes and patient satisfaction.<sup id="cite_ref-:27_90-0" class="reference"><a href="#cite_note-:27-90">&#91;90&#93;</a></sup> <sup id="cite_ref-:28_91-0" class="reference"><a href="#cite_note-:28-91">&#91;91&#93;</a></sup> Despite this, patient acceptance of surgery in developing countries is highly variable and often low.<sup id="cite_ref-:22_81-1" class="reference"><a href="#cite_note-:22-81">&#91;81&#93;</a></sup> <sup id="cite_ref-:27_90-1" class="reference"><a href="#cite_note-:27-90">&#91;90&#93;</a></sup> <sup id="cite_ref-:28_91-1" class="reference"><a href="#cite_note-:28-91">&#91;91&#93;</a></sup> Patient-related barriers to surgery include unfamiliarity with glaucoma, absence of symptoms at time of diagnosis, and fear of complications. Due to a lack of knowledge about the disease, many newly diagnosed patients with end-stage glaucoma in their worse eye decline potentially vision-saving surgery on their better eye.
</p><p>One survey of Nigerian ophthalmologists identified multiple surgeon-specific concerns that may act as barriers to surgical intervention as well, including concern about lack of patient satisfaction, complications of surgery, and negative publicity.<sup id="cite_ref-:23_83-1" class="reference"><a href="#cite_note-:23-83">&#91;83&#93;</a></sup> Such concerns are not unfounded. Glaucoma surgery is designed to prevent vision loss, but patients with glaucoma who lack eye health literacy often have an expectation for sight restoration, such as through spectacles or cataract surgery. In practice, performing incisional glaucoma surgery on patients in a population where there is little understanding of eye diseases can potentially discourage patients with cataract blindness and other reversible causes of vision loss from seeking eye care. Nevertheless, glaucoma surgery acceptance rates can substantially increase when patients are properly educated about the disease at the time of diagnosis.<sup id="cite_ref-:27_90-2" class="reference"><a href="#cite_note-:27-90">&#91;90&#93;</a></sup>
</p><p>Trabeculectomy is the most common glaucoma surgery performed in the developing world.<sup id="cite_ref-:25_88-1" class="reference"><a href="#cite_note-:25-88">&#91;88&#93;</a></sup> <sup id="cite_ref-:29_92-0" class="reference"><a href="#cite_note-:29-92">&#91;92&#93;</a></sup> <sup id="cite_ref-:30_93-0" class="reference"><a href="#cite_note-:30-93">&#91;93&#93;</a></sup> <sup id="cite_ref-94" class="reference"><a href="#cite_note-94">&#91;94&#93;</a></sup> When performed with antimetabolites (e.g. mitomycin C or 5-fluorouracil), the surgery has a reasonably high rate of providing significant long-term IOP reduction.<sup id="cite_ref-95" class="reference"><a href="#cite_note-95">&#91;95&#93;</a></sup> <sup id="cite_ref-:31_96-0" class="reference"><a href="#cite_note-:31-96">&#91;96&#93;</a></sup> Trabeculectomy is arguably the most cost-effective glaucoma intervention because it requires minimal equipment, does not involve the implantation of a device that may be prohibitively expensive or difficult to obtain, and often obviates the need for long-term medical management.<sup id="cite_ref-:26_89-1" class="reference"><a href="#cite_note-:26-89">&#91;89&#93;</a></sup> The surgery is highly effective for not only open-angle glaucoma but also for angle-closure forms of the disease; in countries with a high incidence of angle-closure glaucoma (ACG) such as China, trabeculectomy is the preferred first-line treatment for PACG with significant peripheral anterior synechiae.<sup id="cite_ref-:16_13-1" class="reference"><a href="#cite_note-:16-13">&#91;13&#93;</a></sup>
</p><p>Modifications to what many surgeons in developed countries would consider a “standard” trabeculectomy technique are common in resource-limited parts of the world. Surgeons often employ releasable sutures due to the unavailability of lasers for suture lysis.<sup id="cite_ref-:28_91-2" class="reference"><a href="#cite_note-:28-91">&#91;91&#93;</a></sup> Releasable sutures also enable a tighter suturing of the scleral flap, which reduces the incidence of postoperative hypotony and its sequelae, including the acceleration of cataract formation.<sup id="cite_ref-97" class="reference"><a href="#cite_note-97">&#91;97&#93;</a></sup> Even with optimal technique, trabeculectomy in any form is cataractogenic, especially when antimetabolites are used. Patients in the developing world also frequently present with both visually significant cataracts and glaucoma. To address both issues, techniques have been developed that combine manual small incision cataract surgery (MSICS) with trabeculectomy.<sup id="cite_ref-98" class="reference"><a href="#cite_note-98">&#91;98&#93;</a></sup> Some have advocated for the use of beta radiation as an alternative to antimetabolites in developing countries because a radiation delivery device is reusable, durable, and does not depend on regular supply of medication.<sup id="cite_ref-:21_79-1" class="reference"><a href="#cite_note-:21-79">&#91;79&#93;</a></sup> <sup id="cite_ref-:30_93-1" class="reference"><a href="#cite_note-:30-93">&#91;93&#93;</a></sup>
</p><p>There is an increased risk of trabeculectomy failure in African eyes compared to Caucasian eyes.<sup id="cite_ref-99" class="reference"><a href="#cite_note-99">&#91;99&#93;</a></sup> <sup id="cite_ref-100" class="reference"><a href="#cite_note-100">&#91;100&#93;</a></sup> While the use of antimetabolites significantly reduce the risk of failure, this racial difference may not be present with tube-shunt surgery.<sup id="cite_ref-101" class="reference"><a href="#cite_note-101">&#91;101&#93;</a></sup> <sup id="cite_ref-102" class="reference"><a href="#cite_note-102">&#91;102&#93;</a></sup> A small group of adult and pediatric cases receiving the Ahmed valve implant in Kenya showed IOP reduction from a mean of 36.4 mmHg to 16.7 mmHg along with a decrease in medication requirement and only one major complication.<sup id="cite_ref-103" class="reference"><a href="#cite_note-103">&#91;103&#93;</a></sup> In Ethiopia, a series of patients with refractory glaucoma received tube-shunt placement surgery and experienced similar success.<sup id="cite_ref-104" class="reference"><a href="#cite_note-104">&#91;104&#93;</a></sup> Given the decreased follow-up burden with tube placement as compared to trabeculectomy, decreased need for reoperation, and comparable number of medications needed to maintain goal IOP; tube placement may be a viable choice for disease management in developing countries.<sup id="cite_ref-:31_96-1" class="reference"><a href="#cite_note-:31-96">&#91;96&#93;</a></sup> <sup id="cite_ref-105" class="reference"><a href="#cite_note-105">&#91;105&#93;</a></sup> Potential barriers to tube-shunt placement in the developing world are added cost, access to the device, and access to the donor tissues typically used to cover the tube at its entry site (e.g. cornea, sclera and pericardium). Aurolab, the nonprofit manufacturing unit of the Aravind Eye Care System, manufactures the Aravind Aqueous Drainage Device, a valveless tube-shunt that is comparable to the Baerveldt 350 glaucoma implant. This device is sold throughout the world for approximately US$50 - a fraction of the cost of other glaucoma tube-shunts.
</p><p>Recent research on the use of intracameral moxifloxacin as the last step of cataract and glaucoma surgery in the developing world has found a robust decrease in the incidence of postoperative endophthalmitis.<sup id="cite_ref-106" class="reference"><a href="#cite_note-106">&#91;106&#93;</a></sup> One retrospective study reported a nearly 4-fold reduction in early endophthalmitis following trabeculectomy or combined trabeculectomy/cataract extraction surgery.<sup id="cite_ref-107" class="reference"><a href="#cite_note-107">&#91;107&#93;</a></sup> In response, many surgeons and eye care systems throughout the world have adopted intracameral moxifloxacin as standard practice for glaucoma surgery.
</p><p>For ACG, cataract extraction with or without trabeculectomy may be a reasonable surgical option. The crystalline lens plays a major mechanistic role in ACG by virtue of its size, in effect mechanically crowding anatomically narrow-angled eyes. Additionally, because trabeculectomy accelerates the development of cataract, combining the two surgeries or simply performing standalone cataract extraction may provide better long-term visual outcomes in developing regions where patient follow-up is poor. One randomized controlled trial of eyes with medically controlled primary angle-closure glaucoma (PACG) and cataract, demonstrated that phacoemulsification alone garnered IOP reductions similar to combined phacoemulsification/trabeculectomy.<sup id="cite_ref-108" class="reference"><a href="#cite_note-108">&#91;108&#93;</a></sup> In a related study of eyes with medically uncontrolled PACG, the combined surgery group had greater IOP reductions than the standalone phacoemulsification group. Notably, phaco-trabeculectomy also yielded more complications.<sup id="cite_ref-109" class="reference"><a href="#cite_note-109">&#91;109&#93;</a></sup>
</p><p>Clear lens extraction for the treatment of angle-closure glaucoma is controversial. In younger patients, clear lens extraction results in the loss of accommodation and also confers a higher risk of rhegmatogenous retinal detachment.<sup id="cite_ref-110" class="reference"><a href="#cite_note-110">&#91;110&#93;</a></sup> Nevertheless, one prominent multicenter randomized controlled trial found that for the management of PACG and primary angle closure with elevated IOP, clear-lens extraction had superior outcomes and was more cost-effective than laser peripheral iridotomy.<sup id="cite_ref-111" class="reference"><a href="#cite_note-111">&#91;111&#93;</a></sup> Another randomized controlled trial investigating management of uncontrolled PACG in eyes without cataract found that trabeculectomy was superior to phacoemulsification in terms of IOP and medication reduction.<sup id="cite_ref-112" class="reference"><a href="#cite_note-112">&#91;112&#93;</a></sup> However, trabeculectomy also was associated with more complications in the study.
</p><p>Management of neovascular glaucoma (NVG) is notoriously difficult in any setting. In general, glaucoma drainage implants are considered more effective than trabeculectomy in treating NVG because fibrovascular membranes can grow over and obstruct trabeculectomy sclerostomy sites. However, trabeculectomy can successfully treat NVG in the developing world, especially when antifibrotics and anti-VEGF agents are also used.<sup id="cite_ref-113" class="reference"><a href="#cite_note-113">&#91;113&#93;</a></sup> Multiple challenges limit the use of bevacizumab and other anti-VEGF agents in the developing world, including cost, availability, and the need for refrigerated storage.
</p>
<h3><span class="mw-headline" id="Lasers">Lasers</span></h3>
<p>Selective laser trabeculoplasty (SLT) is popular in settings where the necessary equipment is available. In a population of African descent in St. Lucia, SLT treatment of patients with open-angle glaucoma had a success rate of 77.7%, with success defined as at least 10% reduction in IOP. About half of the successful eyes had at least a 40% reduction in IOP from post-washout baseline.<sup id="cite_ref-114" class="reference"><a href="#cite_note-114">&#91;114&#93;</a></sup> A Chinese study of SLT reported a success rate of 53%, using an IOP reduction of at least 20% as the cutoff for success.<sup id="cite_ref-115" class="reference"><a href="#cite_note-115">&#91;115&#93;</a></sup> In Africa and other developing regions of the world, SLT may be a better alternative to surgery than medical therapy because of the considerable challenges with medication compliance in resource-limited countries.<sup id="cite_ref-116" class="reference"><a href="#cite_note-116">&#91;116&#93;</a></sup>
</p><p>Laser peripheral iridotomy (LPI), where available, is a reasonable and relatively safe alternative to surgery for the management of primary angle-closure or “early” PACG. However, there is growing evidence that PACG with definite glaucomatous optic neuropathy does not respond well to LPI. One recent review of the literature found that in 68% to 94% of PACG patients initially treated with LPI, the IOP actually increased at 6 months post-laser.<sup id="cite_ref-:16_13-2" class="reference"><a href="#cite_note-:16-13">&#91;13&#93;</a></sup> Reflecting this reality, Chinese medical textbooks generally recommend trabeculectomy as the first-line treatment for PACG with peripheral anterior synechiae &gt; 180 degrees.
</p><p>Cyclodestructive procedures generally are viewed as last-line treatment for patients with poor vision due to their side-effect profile (i.e. uveitis, cataract, ischemia, hypotony, phthisis), but there has been some support for using cyclophotocoagulation as first-line treatment in developing countries.<sup id="cite_ref-117" class="reference"><a href="#cite_note-117">&#91;117&#93;</a></sup> In Malawi, 47 eyes with primary open-angle or pseudoexfoliative glaucoma were treated with low-dose transscleral diode laser cyclophotocoagulation. Half of these patients maintained an IOP reduction of at least 25% at 3 months.<sup id="cite_ref-118" class="reference"><a href="#cite_note-118">&#91;118&#93;</a></sup> Similar results were reported in Tanzania and Cameroon.<sup id="cite_ref-119" class="reference"><a href="#cite_note-119">&#91;119&#93;</a></sup> <sup id="cite_ref-120" class="reference"><a href="#cite_note-120">&#91;120&#93;</a></sup> The development of micropulse transscleral diode lasers such as the MicroPulse P3 (Iridex, Mountain View, CA) offers an additional alternative to medication and incisional surgery.<sup id="cite_ref-121" class="reference"><a href="#cite_note-121">&#91;121&#93;</a></sup> Because micropulse lasers are less destructive than traditional continuous wave diode lasers, they have a better safety profile, but the IOP-lowering effects are not as robust and may not be as sustained.
</p>
<h1><span class="mw-headline" id="Potential_solutions_and_future_directives">Potential solutions and future directives</span></h1>
<h3><span class="mw-headline" id="Diagnosis_2">Diagnosis</span></h3>
<p>Despite recent efforts such as the VISION 2020 global initiative to eliminate avoidable blindness, most people with glaucoma remain undiagnosed.<sup id="cite_ref-:17_14-1" class="reference"><a href="#cite_note-:17-14">&#91;14&#93;</a></sup> Because population-based screening is resource-prohibitive, the WHO and many global ophthalmology experts advocate for enhanced opportunistic screening.<sup id="cite_ref-:19_77-1" class="reference"><a href="#cite_note-:19-77">&#91;77&#93;</a></sup> For example, a cost-effective strategy at improving glaucoma diagnosis rates is the promotion of comprehensive eye examinations for people all above 40 years of age.<sup id="cite_ref-:20_78-2" class="reference"><a href="#cite_note-:20-78">&#91;78&#93;</a></sup> The development of novel technologies and the repurposing of existing technologies offer considerable promise for improving glaucoma diagnostics in the developing world.
</p>
<h3><span class="mw-headline" id="Teleglaucoma">Teleglaucoma</span></h3>
<p>The SARS-CoV-2/COVID-19 pandemic has had a profound impact on global healthcare, and ophthalmology is one of the most impacted medical specialties.<sup id="cite_ref-122" class="reference"><a href="#cite_note-122">&#91;122&#93;</a></sup> <sup id="cite_ref-123" class="reference"><a href="#cite_note-123">&#91;123&#93;</a></sup> With social distancing measures in place, ophthalmology practices in both developing and developed countries have rapidly adopted telemedicine out of necessity.<sup id="cite_ref-:32_124-0" class="reference"><a href="#cite_note-:32-124">&#91;124&#93;</a></sup> <sup id="cite_ref-:33_125-0" class="reference"><a href="#cite_note-:33-125">&#91;125&#93;</a></sup> <sup id="cite_ref-:34_126-0" class="reference"><a href="#cite_note-:34-126">&#91;126&#93;</a></sup> <sup id="cite_ref-:35_127-0" class="reference"><a href="#cite_note-:35-127">&#91;127&#93;</a></sup> <sup id="cite_ref-:36_128-0" class="reference"><a href="#cite_note-:36-128">&#91;128&#93;</a></sup> <sup id="cite_ref-129" class="reference"><a href="#cite_note-129">&#91;129&#93;</a></sup> <sup id="cite_ref-130" class="reference"><a href="#cite_note-130">&#91;130&#93;</a></sup>
</p><p>Notable advantages of teleophthalmology, not necessarily limited to times of crisis, include decentralization of care, cost-efficiency, time-efficiency, and high patient satisfaction.<sup id="cite_ref-:32_124-1" class="reference"><a href="#cite_note-:32-124">&#91;124&#93;</a></sup> <sup id="cite_ref-:33_125-1" class="reference"><a href="#cite_note-:33-125">&#91;125&#93;</a></sup> <sup id="cite_ref-:34_126-1" class="reference"><a href="#cite_note-:34-126">&#91;126&#93;</a></sup> <sup id="cite_ref-:35_127-1" class="reference"><a href="#cite_note-:35-127">&#91;127&#93;</a></sup> <sup id="cite_ref-:36_128-1" class="reference"><a href="#cite_note-:36-128">&#91;128&#93;</a></sup> <sup id="cite_ref-:37_131-0" class="reference"><a href="#cite_note-:37-131">&#91;131&#93;</a></sup> <sup id="cite_ref-:38_132-0" class="reference"><a href="#cite_note-:38-132">&#91;132&#93;</a></sup> <sup id="cite_ref-:39_133-0" class="reference"><a href="#cite_note-:39-133">&#91;133&#93;</a></sup> <sup id="cite_ref-:40_134-0" class="reference"><a href="#cite_note-:40-134">&#91;134&#93;</a></sup> Potential advantages unique to resource-limited and remote areas worldwide include expanded access to expert eye care, facilitation of medical management as an alternative to surgery, and improved disease outcomes.<sup id="cite_ref-:41_135-0" class="reference"><a href="#cite_note-:41-135">&#91;135&#93;</a></sup> <sup id="cite_ref-:42_136-0" class="reference"><a href="#cite_note-:42-136">&#91;136&#93;</a></sup> <sup id="cite_ref-:43_137-0" class="reference"><a href="#cite_note-:43-137">&#91;137&#93;</a></sup> <sup id="cite_ref-:44_138-0" class="reference"><a href="#cite_note-:44-138">&#91;138&#93;</a></sup> <sup id="cite_ref-:45_139-0" class="reference"><a href="#cite_note-:45-139">&#91;139&#93;</a></sup> <sup id="cite_ref-:46_140-0" class="reference"><a href="#cite_note-:46-140">&#91;140&#93;</a></sup> These benefits are particularly relevant for the subspecialty of glaucoma due to its heavy reliance on testing to guide management decisions.<sup id="cite_ref-:47_141-0" class="reference"><a href="#cite_note-:47-141">&#91;141&#93;</a></sup>
</p><p>Teleophthalmology has been implemented in some developing countries with success, albeit on a limited scale. Two commonly employed telemedicine models are “real-time” and “store-and-forward.” In a “real-time” model, healthcare professionals and patients directly interact via audio or audiovisual communications. This interaction may include live collection of objective data such as visual acuity. In a “store-and-forward” model, patients receive a diagnostic workup at a remote ophthalmic testing center or primary health care center equipped with the necessary diagnostic equipment. This workup is then sent electronically to healthcare professionals elsewhere, such as in major eye centers, where the data is interpreted at a later time.<sup id="cite_ref-142" class="reference"><a href="#cite_note-142">&#91;142&#93;</a></sup> <sup id="cite_ref-143" class="reference"><a href="#cite_note-143">&#91;143&#93;</a></sup> <sup id="cite_ref-144" class="reference"><a href="#cite_note-144">&#91;144&#93;</a></sup> <sup id="cite_ref-145" class="reference"><a href="#cite_note-145">&#91;145&#93;</a></sup> For example, a store-and-forward teleglaucoma program utilizing Van Herick angle grading in combination with pachymetry has been shown to have an acceptable sensitivity and specificity for diagnosing occludable angles.<sup id="cite_ref-146" class="reference"><a href="#cite_note-146">&#91;146&#93;</a></sup> Store-and-forward teleophthalmology has been successfully implemented in long-term, remote care of glaucoma patients.<sup id="cite_ref-147" class="reference"><a href="#cite_note-147">&#91;147&#93;</a></sup> Real-time video visits with data from remote testing centers can help guide management without the need to bring the patient in office, unless there are signs of worsening. <sup id="cite_ref-:47_141-1" class="reference"><a href="#cite_note-:47-141">&#91;141&#93;</a></sup> <sup id="cite_ref-148" class="reference"><a href="#cite_note-148">&#91;148&#93;</a></sup>
</p><p>Widespread implementation teleophthalmology remains a considerable challenge in resource-limited regions of the world, in part due to inadequate telecommunications infrastructure and poor integration of ophthalmology with existing healthcaresystems.<sup id="cite_ref-:41_135-1" class="reference"><a href="#cite_note-:41-135">&#91;135&#93;</a></sup> <sup id="cite_ref-:42_136-1" class="reference"><a href="#cite_note-:42-136">&#91;136&#93;</a></sup> <sup id="cite_ref-:43_137-1" class="reference"><a href="#cite_note-:43-137">&#91;137&#93;</a></sup> <sup id="cite_ref-:44_138-1" class="reference"><a href="#cite_note-:44-138">&#91;138&#93;</a></sup> <sup id="cite_ref-:45_139-1" class="reference"><a href="#cite_note-:45-139">&#91;139&#93;</a></sup> <sup id="cite_ref-:46_140-1" class="reference"><a href="#cite_note-:46-140">&#91;140&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Smartphone-based_testing">Smartphone-based testing</span></h4>
<p>Smartphone-based glaucoma testing is a promising area of diagnostics. Such technology’s portability, relatively low cost, and potential use without the physical presence of an ophthalmic specialist make smartphone-based testing attractive for serving rural and under-resourced populations. Furthermore, the increasing ubiquity and sophistication of smartphones potentially enables widespread adoption of such technologies in developing countries.<sup id="cite_ref-:37_131-1" class="reference"><a href="#cite_note-:37-131">&#91;131&#93;</a></sup> <sup id="cite_ref-:38_132-1" class="reference"><a href="#cite_note-:38-132">&#91;132&#93;</a></sup> <sup id="cite_ref-:39_133-1" class="reference"><a href="#cite_note-:39-133">&#91;133&#93;</a></sup> <sup id="cite_ref-:40_134-1" class="reference"><a href="#cite_note-:40-134">&#91;134&#93;</a></sup> The use of smartphone photography for ocular imaging has been validated as safe.<sup id="cite_ref-149" class="reference"><a href="#cite_note-149">&#91;149&#93;</a></sup> Smartphone photography for anterior segment screening examination,<sup id="cite_ref-150" class="reference"><a href="#cite_note-150">&#91;150&#93;</a></sup> <sup id="cite_ref-151" class="reference"><a href="#cite_note-151">&#91;151&#93;</a></sup> gonio-imaging,<sup id="cite_ref-152" class="reference"><a href="#cite_note-152">&#91;152&#93;</a></sup> and fundus and disc assessment<sup id="cite_ref-:37_131-2" class="reference"><a href="#cite_note-:37-131">&#91;131&#93;</a></sup> <sup id="cite_ref-153" class="reference"><a href="#cite_note-153">&#91;153&#93;</a></sup> <sup id="cite_ref-154" class="reference"><a href="#cite_note-154">&#91;154&#93;</a></sup> <sup id="cite_ref-155" class="reference"><a href="#cite_note-155">&#91;155&#93;</a></sup> <sup id="cite_ref-156" class="reference"><a href="#cite_note-156">&#91;156&#93;</a></sup> <sup id="cite_ref-157" class="reference"><a href="#cite_note-157">&#91;157&#93;</a></sup> <sup id="cite_ref-158" class="reference"><a href="#cite_note-158">&#91;158&#93;</a></sup> <sup id="cite_ref-159" class="reference"><a href="#cite_note-159">&#91;159&#93;</a></sup> has been described in the literature. Smartphone and tablet-based visual field applications such as Melbourne Rapid Fields (MRF) have been developed and offer screening comparable to tangent screen testing.<sup id="cite_ref-160" class="reference"><a href="#cite_note-160">&#91;160&#93;</a></sup> Virtual reality based visual field testing also may be a portable alternative to office based visual field testing, with the added benefit of gaze tracking capabilities.<sup id="cite_ref-161" class="reference"><a href="#cite_note-161">&#91;161&#93;</a></sup> Proof-of-concept smartphone systems have even demonstrated the potential to estimate IOP with reasonable accuracy.<sup id="cite_ref-162" class="reference"><a href="#cite_note-162">&#91;162&#93;</a></sup>
</p>
<h4><span id="Artifical_intelligence_(AI)_and_deep_learning"></span><span class="mw-headline" id="Artifical_intelligence_.28AI.29_and_deep_learning">Artifical intelligence (AI) and deep learning</span></h4>
<p>New avenues with automated glaucoma screening and diagnostics are being explored using machine learning and AI. In settings where specialist care is scant, artificial intelligence may provide potentially powerful screening and diagnostic tools that can be integrated with existing primary care delivery models in the developing world.<sup id="cite_ref-163" class="reference"><a href="#cite_note-163">&#91;163&#93;</a></sup> <sup id="cite_ref-164" class="reference"><a href="#cite_note-164">&#91;164&#93;</a></sup> <sup id="cite_ref-165" class="reference"><a href="#cite_note-165">&#91;165&#93;</a></sup> The division of machine learning that focuses on imaging is deep learning. Possible barriers to widespread application include cost of development and implementation as well as a lack of an ethnically diverse data set.<sup id="cite_ref-:48_166-0" class="reference"><a href="#cite_note-:48-166">&#91;166&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Patient_education_and_awareness">Patient education and awareness</span></h3>
<p>One of the largest barriers to eye care in developing countries is the lack of community awareness about common eye diseases and their treatment. Currently there is widespread lack of understanding regarding glaucoma’s causes, symptoms, and natural history. In a multicenter study from Nigeria, only 46% of patients were aware that glaucoma causes vision loss and 73% believed that vision loss due to glaucoma was reversible.<sup id="cite_ref-:29_92-1" class="reference"><a href="#cite_note-:29-92">&#91;92&#93;</a></sup> In Botswana, 11.5% of patients with previously diagnosed glaucoma had ever heard of the disease before the diagnosis and 36% still did not understand the disease after being diagnosed.<sup id="cite_ref-:15_8-1" class="reference"><a href="#cite_note-:15-8">&#91;8&#93;</a></sup> In India, awareness, or being familiar with the term glaucoma, was found to be 2.3% in an urban population and 0.32% in a rural population.<sup id="cite_ref-167" class="reference"><a href="#cite_note-167">&#91;167&#93;</a></sup> <sup id="cite_ref-168" class="reference"><a href="#cite_note-168">&#91;168&#93;</a></sup> All of these numbers are much lower than the awareness and understanding of disease reported from developed countries.<sup id="cite_ref-169" class="reference"><a href="#cite_note-169">&#91;169&#93;</a></sup> <sup id="cite_ref-170" class="reference"><a href="#cite_note-170">&#91;170&#93;</a></sup> Lack of patient knowledge about glaucoma has been linked to refusal of surgery, poor medication adherence, more psychological depression, and a lower quality of life.<sup id="cite_ref-171" class="reference"><a href="#cite_note-171">&#91;171&#93;</a></sup> <sup id="cite_ref-172" class="reference"><a href="#cite_note-172">&#91;172&#93;</a></sup> <sup id="cite_ref-173" class="reference"><a href="#cite_note-173">&#91;173&#93;</a></sup> To address this knowledge gap, glaucoma experts have called for the development of culture-specific marketing and other local glaucoma public service awareness programs that increase general knowledge about glaucoma and promote routine vision screening.<sup id="cite_ref-:20_78-3" class="reference"><a href="#cite_note-:20-78">&#91;78&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Medical_management_2">Medical management</span></h3>
<p>As in developed countries, medication adherence in the developing world is a major obstacle to nonsurgical management of glaucoma. The recent development of sustained-release drug delivery systems such as bimatoprost SR (Allergan, Dublin, Ireland) portends considerable promise, although the current cost and availability of such medications all but preclude their use in resource-limited settings.<sup id="cite_ref-174" class="reference"><a href="#cite_note-174">&#91;174&#93;</a></sup> Lowering the cost and improving the quality of generic ophthalmic medications throughout the developing world is critical to more widespread medical management of glaucoma. Earlier diagnosis and improved monitoring such as via emerging teleglaucoma technologies may increase the role of medications worldwide.
</p>
<h3><span class="mw-headline" id="Eye_care_professional_education">Eye care professional education</span></h3>
<p>The expansion of professional eye care education is critical to adequately addressing glaucoma in the developing world. While most countries have increased their total number of eye care professionals in recent years, the number of ophthalmologists, optometrists, and other eye care professionals remains inadequate.<sup id="cite_ref-:19_77-2" class="reference"><a href="#cite_note-:19-77">&#91;77&#93;</a></sup> In particular, increasing the numbers of ophthalmic paraprofessionals in resource-limited countries is essential to providing the routine vision screenings necessary to detect and treat glaucoma. Improved distribution of eye care professionals is also needed to address the world’s uneven distribution of glaucoma and other eye diseases. One global survey found that two thirds of the world’s ophthalmologists reside in just 13 countries.<sup id="cite_ref-175" class="reference"><a href="#cite_note-175">&#91;175&#93;</a></sup>
</p><p>To improve quality of ophthalmic training in developing countries, which can be variable, some countries such as several in Eastern, Central, and Southern Africa have made recent efforts at standardizing training curricula.<sup id="cite_ref-176" class="reference"><a href="#cite_note-176">&#91;176&#93;</a></sup><sup> </sup>The expanded use of structured wet lab courses and specialized artificial eyes also may play a key role in the improved quality and volume of eye surgeon training in areas of greatest need.<sup id="cite_ref-177" class="reference"><a href="#cite_note-177">&#91;177&#93;</a></sup> Some ophthalmology institutions including Aravind Eye Hospitals in India, Tilganga Institute of Ophthalmology in Nepal, LV Prasad Eye Institute in India, Byers Eye Institute at Stanford University, and Moran Eye Center at the University of Utah have created global ophthalmology fellowships and international observership programs as a means of improving ophthalmology training in developing countries. Orbis International, a nonprofit organization based out of the United States, fosters skills transfer to eyecare professionals in developing countries via its “Flying Eye Hospital” MD-10 aircraft and via Cybersight, Orbis’s teleophthalmology and online education platform.<sup id="cite_ref-178" class="reference"><a href="#cite_note-178">&#91;178&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Eye_care_integration_into_existing_systems">Eye care integration into existing systems</span></h3>
<p>Since 1984, the WHO has recommended integrating eye care into existing healthcare systems.<sup id="cite_ref-:49_179-0" class="reference"><a href="#cite_note-:49-179">&#91;179&#93;</a></sup> Specifically, many experts advocate for expanding the role that primary care systems play in detecting common eye diseases such as glaucoma.<sup id="cite_ref-:17_14-2" class="reference"><a href="#cite_note-:17-14">&#91;14&#93;</a></sup> Such an approach is not necessarily straightforward, and unfortunately in places like Africa, little ground has been gained since 1984 toward these ends.<sup id="cite_ref-:49_179-1" class="reference"><a href="#cite_note-:49-179">&#91;179&#93;</a></sup> Most primary health workers worldwide have poor knowledge of glaucoma. Existing healthcare systems are often resource-limited as it is, so the added burden of screening for eye diseases may not be feasible without additional financial and material resources. Even when primary care physicians in developing countries identify vision issues, referral pathways to an eye care specialist are often lacking.<sup id="cite_ref-:24_84-1" class="reference"><a href="#cite_note-:24-84">&#91;84&#93;</a></sup>
</p><p>Successful, self-sustaining models for comprehensive eye care in the developing world do exist, such as LV Prasad Eye Institute, Tilganga Institute of Ophthalmology, and Aravind Eye Hospitals.<sup id="cite_ref-:24_84-2" class="reference"><a href="#cite_note-:24-84">&#91;84&#93;</a></sup> <sup id="cite_ref-180" class="reference"><a href="#cite_note-180">&#91;180&#93;</a></sup> These eye care systems are multi-tiered and have excellent referral pathways, from village screenings to dedicated eye hospitals. Eye care for the poor is cross-subsidized by eye care for those who can pay and elect for premium services. Organizing glaucoma care into multiple levels of care such that screening is performed at a primary level, medical care is performed at a secondary level, and surgery is performed a tertiary level, enables a broader reach of eye care into rural and resource-limited regions.<sup id="cite_ref-:20_78-4" class="reference"><a href="#cite_note-:20-78">&#91;78&#93;</a></sup> The Indian government’s m-Health mobile telemedicine system may constitute a viable model for glaucoma management in developing countries, especially as internet access becomes more ubiquitous.<sup id="cite_ref-181" class="reference"><a href="#cite_note-181">&#91;181&#93;</a></sup> Artificial intelligence- and machine learning algorithm-assisted interpretation of ophthalmic imaging may play a critical role in making glaucoma screening affordable and accessible in remote parts of the world.<sup id="cite_ref-:48_166-1" class="reference"><a href="#cite_note-:48-166">&#91;166&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Conclusion">Conclusion</span></h1>
<p>Glaucoma continues to pose a major challenge in developing countries. Unlike blindness related to vitamin A deficiency, onchocerciasis, and other vision-impairing diseases that have been addressed through public health initiatives, glaucoma management requires one-on-one care from an eye care specialist. Unlike cataract blindness, which can be reversed permanently with a single surgery, glaucoma care generally necessitates routine follow-up for monitoring of disease progression, medication adjustments, procedures, and/or surgeries. Emphasis should be placed on training, educating, and mobilizing existing non-ophthalmology health care systems. Improved training and retention of eye care specialists in developing countries is critical to expanding global access to glaucoma care. Further development of teleglaucoma and its successful integration into existing models of healthcare delivery may dramatically improve access to eye care in resource-limited countries. Continued efforts through multinational initiatives, public health education, professional training programs, and programs focused on early disease detection and treatment are all needed for vision loss to be decreased in the developing world. Since glaucoma is more prevalent in many developing countries than in the developed world, it should be a core focus of any campaign aimed at improving eye health.
</p>
<h1><span class="mw-headline" id="Additional_Resources">Additional Resources</span></h1>
<ul><li> International Association for the Prevention of Blindness. Vision Atlas. https://www.iapb.org/learn/vision-atlas. Accessed  November 11, 2020.</li></ul>
<h1><span class="mw-headline" id="References">References</span></h1>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-:0-1"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:0_1-0">1.0</a></sup> <sup><a href="#cite_ref-:0_1-1">1.1</a></sup></span> <span class="reference-text">Flaxman SR, Bourne RR, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. <i>The Lancet Global Health</i> 2017; <b>5</b>(12): e1221-e34.</span>
</li>
<li id="cite_note-:1-2"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:1_2-0">2.0</a></sup> <sup><a href="#cite_ref-:1_2-1">2.1</a></sup></span> <span class="reference-text">Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. <i>Ophthalmology</i> 2014; <b>121</b>(11): 2081-90.</span>
</li>
<li id="cite_note-3"><span class="mw-cite-backlink"><a href="#cite_ref-3">↑</a></span> <span class="reference-text">Chen PP. Risk and risk factors for blindness from glaucoma. <i>Current opinion in ophthalmology</i> 2004; <b>15</b>(2): 107-11.</span>
</li>
<li id="cite_note-4"><span class="mw-cite-backlink"><a href="#cite_ref-4">↑</a></span> <span class="reference-text">Omoti A, Osahon A, Waziri-Erameh M. Pattern of presentation of primary open-angle glaucoma in Benin City, Nigeria. <i>Tropical doctor</i> 2006; <b>36</b>(2): 97-100.</span>
</li>
<li id="cite_note-5"><span class="mw-cite-backlink"><a href="#cite_ref-5">↑</a></span> <span class="reference-text">Ackland P. The accomplishments of the global initiative VISION 2020: The Right to Sight and the focus for the next 8 years of the campaign. <i>Indian journal of ophthalmology</i> 2012; <b>60</b>(5): 380.</span>
</li>
<li id="cite_note-6"><span class="mw-cite-backlink"><a href="#cite_ref-6">↑</a></span> <span class="reference-text">Palmer JJ, Chinanayi F, Gilbert A, et al. Trends and implications for achieving VISION 2020 human resources for eye health targets in 16 countries of sub-Saharan Africa by the year 2020. <i>Human resources for health</i> 2014; <b>12</b>(1): 45.</span>
</li>
<li id="cite_note-7"><span class="mw-cite-backlink"><a href="#cite_ref-7">↑</a></span> <span class="reference-text">Palmer JJ, Chinanayi F, Gilbert A, et al. Mapping human resources for eye health in 21 countries of sub-Saharan Africa: current progress towards VISION 2020. <i>Human resources for health</i> 2014; <b>12</b>(1): 44.</span>
</li>
<li id="cite_note-:15-8"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:15_8-0">8.0</a></sup> <sup><a href="#cite_ref-:15_8-1">8.1</a></sup></span> <span class="reference-text">Jackson DJ, Razai MS, Falama R, et al. The clinical characteristics of patients with glaucoma presenting to Botswana healthcare facilities: an observational study. <i>BMJ open</i> 2014; <b>4</b>(12).</span>
</li>
<li id="cite_note-9"><span class="mw-cite-backlink"><a href="#cite_ref-9">↑</a></span> <span class="reference-text">Isawumi MA, Hassan MB, Akinwusi PO, et al. Awareness of and Attitude towards glaucoma among an adult rural population of Osun State, Southwest Nigeria. <i>Middle East African journal of ophthalmology</i> 2014; <b>21</b>(2): 165.</span>
</li>
<li id="cite_note-10"><span class="mw-cite-backlink"><a href="#cite_ref-10">↑</a></span> <span class="reference-text">Shrestha MK, Guo CW, Maharjan N, Gurung R, Ruit S. Health literacy of common ocular diseases in Nepal. <i>BMC ophthalmology</i> 2014; <b>14</b>(1): 2.</span>
</li>
<li id="cite_note-11"><span class="mw-cite-backlink"><a href="#cite_ref-11">↑</a></span> <span class="reference-text">Ruit S, Tabin G, Wykoff CC. Fighting Global Blindness: Improving World Vision Through Cataract Elimination: American Public Health Association; 2006.</span>
</li>
<li id="cite_note-12"><span class="mw-cite-backlink"><a href="#cite_ref-12">↑</a></span> <span class="reference-text">Adio AO, Onua AA. Economic burden of glaucoma in Rivers State, Nigeria. <i>Clinical ophthalmology (Auckland, NZ)</i> 2012; <b>6</b>: 2023.</span>
</li>
<li id="cite_note-:16-13"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:16_13-0">13.0</a></sup> <sup><a href="#cite_ref-:16_13-1">13.1</a></sup> <sup><a href="#cite_ref-:16_13-2">13.2</a></sup></span> <span class="reference-text">Liang YB, Wang NL, Rong SS, Thomas R. Initial treatment for primary angle-closure glaucoma in China. <i>Journal of glaucoma</i> 2015; <b>24</b>(6): 469-73.</span>
</li>
<li id="cite_note-:17-14"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:17_14-0">14.0</a></sup> <sup><a href="#cite_ref-:17_14-1">14.1</a></sup> <sup><a href="#cite_ref-:17_14-2">14.2</a></sup></span> <span class="reference-text">Bourne RR. Vision 2020: where are we? <i>Current Opinion in Ophthalmology</i> 2020; <b>31</b>(2): 81-4.</span>
</li>
<li id="cite_note-:2-15"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:2_15-0">15.0</a></sup> <sup><a href="#cite_ref-:2_15-1">15.1</a></sup> <sup><a href="#cite_ref-:2_15-2">15.2</a></sup></span> <span class="reference-text">Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. <i>British journal of ophthalmology</i> 2006; <b>90</b>(3): 262-7.</span>
</li>
<li id="cite_note-:3-16"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:3_16-0">16.0</a></sup> <sup><a href="#cite_ref-:3_16-1">16.1</a></sup></span> <span class="reference-text">Bourne RR, Jonas JB, Bron AM, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections. <i>British Journal of Ophthalmology</i> 2018; <b>102</b>(5): 575-85.</span>
</li>
<li id="cite_note-:4-17"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:4_17-0">17.0</a></sup> <sup><a href="#cite_ref-:4_17-1">17.1</a></sup></span> <span class="reference-text">Cheng C-Y, Wang N, Wong TY, et al. Prevalence and causes of vision loss in East Asia in 2015: magnitude, temporal trends and projections. <i>British Journal of Ophthalmology</i> 2020; <b>104</b>(5): 616-22.</span>
</li>
<li id="cite_note-:5-18"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:5_18-0">18.0</a></sup> <sup><a href="#cite_ref-:5_18-1">18.1</a></sup></span> <span class="reference-text">Keeffe JE, Casson RJ, Pesudovs K, et al. Prevalence and causes of vision loss in South-east Asia and Oceania in 2015: magnitude, temporal trends and projections. <i>British Journal of Ophthalmology</i> 2019; <b>103</b>(7): 878-84.</span>
</li>
<li id="cite_note-:6-19"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:6_19-0">19.0</a></sup> <sup><a href="#cite_ref-:6_19-1">19.1</a></sup></span> <span class="reference-text">Leasher JL, Braithwaite T, Furtado JM, et al. Prevalence and causes of vision loss in Latin America and the Caribbean in 2015: magnitude, temporal trends and projections. <i>British Journal of Ophthalmology</i> 2019; <b>103</b>(7): 885-93.</span>
</li>
<li id="cite_note-:7-20"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:7_20-0">20.0</a></sup> <sup><a href="#cite_ref-:7_20-1">20.1</a></sup></span> <span class="reference-text">Naidoo K, Kempen JH, Gichuhi S, et al. Prevalence and causes of vision loss in sub-Saharan Africa in 2015: magnitude, temporal trends and projections. <i>British Journal of Ophthalmology</i> 2020.</span>
</li>
<li id="cite_note-:8-21"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:8_21-0">21.0</a></sup> <sup><a href="#cite_ref-:8_21-1">21.1</a></sup></span> <span class="reference-text">Nangia V, Jonas JB, George R, et al. Prevalence and causes of blindness and vision impairment: magnitude, temporal trends and projections in South and Central Asia. <i>British Journal of Ophthalmology</i> 2019; <b>103</b>(7): 871-7.</span>
</li>
<li id="cite_note-:9-22"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:9_22-0">22.0</a></sup> <sup><a href="#cite_ref-:9_22-1">22.1</a></sup></span> <span class="reference-text">Kosoko-Lasaki O, Gong G, Haynatzki G, Wilson MR. Race, ethnicity and prevalence of primary open-angle glaucoma. <i>Journal of the National Medical Association</i> 2006; <b>98</b>(10): 1626.</span>
</li>
<li id="cite_note-23"><span class="mw-cite-backlink"><a href="#cite_ref-23">↑</a></span> <span class="reference-text">Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore Eye Survey. <i>Jama</i> 1991; <b>266</b>(3): 369-74.</span>
</li>
<li id="cite_note-:10-24"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:10_24-0">24.0</a></sup> <sup><a href="#cite_ref-:10_24-1">24.1</a></sup></span> <span class="reference-text">Cho H-k, Kee C. Population-based glaucoma prevalence studies in Asians. <i>Survey of ophthalmology</i> 2014; <b>59</b>(4): 434-47.</span>
</li>
<li id="cite_note-25"><span class="mw-cite-backlink"><a href="#cite_ref-25">↑</a></span> <span class="reference-text">Foster PJ, Baasanhu J, Alsbirk PH, Munkhbayar D, Uranchimeg D, Johnson GJ. Glaucoma in Mongolia: a population-based survey in Hövsgöl Province, northern Mongolia. <i>Archives of ophthalmology</i> 1996; <b>114</b>(10): 1235-41.</span>
</li>
<li id="cite_note-26"><span class="mw-cite-backlink"><a href="#cite_ref-26">↑</a></span> <span class="reference-text">Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. <i>Ophthalmology</i> 2004; <b>111</b>(9): 1641-8.</span>
</li>
<li id="cite_note-27"><span class="mw-cite-backlink"><a href="#cite_ref-27">↑</a></span> <span class="reference-text">Allingham RR, Liu Y, Rhee DJ. The genetics of primary open-angle glaucoma: a review. <i>Experimental eye research</i> 2009; <b>88</b>(4): 837-44.</span>
</li>
<li id="cite_note-28"><span class="mw-cite-backlink"><a href="#cite_ref-28">↑</a></span> <span class="reference-text">Takamoto M, Araie M. Genetics of primary open angle glaucoma. <i>Japanese journal of ophthalmology</i> 2014; <b>58</b>(1): 1-15.</span>
</li>
<li id="cite_note-29"><span class="mw-cite-backlink"><a href="#cite_ref-29">↑</a></span> <span class="reference-text">Williams SE, Carmichael TR, Allingham RR, Hauser M, Ramsay M. The genetics of POAG in black South Africans: a candidate gene association study. <i>Scientific reports</i> 2015; <b>5</b>(1): 1-7.</span>
</li>
<li id="cite_note-30"><span class="mw-cite-backlink"><a href="#cite_ref-30">↑</a></span> <span class="reference-text">Casson R, Newland H, Muecke J, et al. Prevalence of glaucoma in rural Myanmar: the Meiktila Eye Study. <i>British journal of ophthalmology</i> 2007; <b>91</b>(6): 710-4.</span>
</li>
<li id="cite_note-:11-31"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:11_31-0">31.0</a></sup> <sup><a href="#cite_ref-:11_31-1">31.1</a></sup></span> <span class="reference-text">Cheng J-W, Zong Y, Zeng Y-Y, Wei R-L. The prevalence of primary angle closure glaucoma in adult Asians: a systematic review and meta-analysis. <i>PloS one</i> 2014; <b>9</b>(7): e103222.</span>
</li>
<li id="cite_note-32"><span class="mw-cite-backlink"><a href="#cite_ref-32">↑</a></span> <span class="reference-text">Yazdani S, Akbarian S, Pakravan M, Afrouzifar M. Prevalence of angle closure in siblings of patients with primary angle-closure glaucoma. <i>Journal of glaucoma</i> 2015; <b>24</b>(2): 149-53.</span>
</li>
<li id="cite_note-33"><span class="mw-cite-backlink"><a href="#cite_ref-33">↑</a></span> <span class="reference-text">Amerasinghe N, Zhang J, Thalamuthu A, et al. The heritability and sibling risk of angle closure in Asians. <i>Ophthalmology</i> 2011; <b>118</b>(3): 480-5.</span>
</li>
<li id="cite_note-34"><span class="mw-cite-backlink"><a href="#cite_ref-34">↑</a></span> <span class="reference-text">Kavitha S, Zebardast N, Palaniswamy K, et al. Family history is a strong risk factor for prevalent angle closure in a South Indian population. <i>Ophthalmology</i> 2014; <b>121</b>(11): 2091-7.</span>
</li>
<li id="cite_note-35"><span class="mw-cite-backlink"><a href="#cite_ref-35">↑</a></span> <span class="reference-text">Sihota R, Ghate D, Mohan S, Gupta V, Pandey R, Dada T. Study of biometric parameters in family members of primary angle closure glaucoma patients. <i>Eye</i> 2008; <b>22</b>(4): 521-7.</span>
</li>
<li id="cite_note-36"><span class="mw-cite-backlink"><a href="#cite_ref-36">↑</a></span> <span class="reference-text">Spaeth G. Angle-closure glaucoma in East Asian and European people. Different diseases? <i>Eye</i> 2007; <b>21</b>(1): 99-100.</span>
</li>
<li id="cite_note-37"><span class="mw-cite-backlink"><a href="#cite_ref-37">↑</a></span> <span class="reference-text">Yip JL, Foster PJ. Ethnic differences in primary angle-closure glaucoma. <i>Current opinion in ophthalmology</i> 2006; <b>17</b>(2): 175-80.</span>
</li>
<li id="cite_note-38"><span class="mw-cite-backlink"><a href="#cite_ref-38">↑</a></span> <span class="reference-text">Liza-Sharmini AT, Sharina YN, Dolaboladi A, Zaid N, Azhany Y, Zunaina E. Clinical presentation, severity and progression of primary angle closure in malays. <i>The Medical journal of Malaysia</i> 2014; <b>69</b>(1): 21.</span>
</li>
<li id="cite_note-39"><span class="mw-cite-backlink"><a href="#cite_ref-39">↑</a></span> <span class="reference-text">Azhany MO. Clinical presentation, severity and progression of primary angle closure in Malay and Chinese patients. <i>Med J Malaysia</i> 2014; <b>69</b>(6): 245.</span>
</li>
<li id="cite_note-:12-40"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:12_40-0">40.0</a></sup> <sup><a href="#cite_ref-:12_40-1">40.1</a></sup> <sup><a href="#cite_ref-:12_40-2">40.2</a></sup></span> <span class="reference-text">Gilbert C, Foster A. Childhood blindness in the context of VISION 2020: the right to sight. <i>Bulletin of the World Health Organization</i> 2001; <b>79</b>: 227-32.</span>
</li>
<li id="cite_note-:13-41"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:13_41-0">41.0</a></sup> <sup><a href="#cite_ref-:13_41-1">41.1</a></sup></span> <span class="reference-text">Koay C, Patel D, Tajunisah I, Subrayan V, Lansingh V. A comparative analysis of avoidable causes of childhood blindness in Malaysia with low income, middle income and high income countries. <i>International Ophthalmology</i> 2015; <b>35</b>(2): 201-7.</span>
</li>
<li id="cite_note-42"><span class="mw-cite-backlink"><a href="#cite_ref-42">↑</a></span> <span class="reference-text">Moore DB, Tomkins O, Ben-Zion I. A review of primary congenital glaucoma in the developing world. <i>Survey of ophthalmology</i> 2013; <b>58</b>(3): 278-85.</span>
</li>
<li id="cite_note-:14-43"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:14_43-0">43.0</a></sup> <sup><a href="#cite_ref-:14_43-1">43.1</a></sup></span> <span class="reference-text">Papadopoulos M, Cable N, Rahi J, Khaw PT. The British infantile and childhood glaucoma (BIG) eye study. <i>Investigative ophthalmology &amp; visual science</i> 2007; <b>48</b>(9): 4100-6.</span>
</li>
<li id="cite_note-44"><span class="mw-cite-backlink"><a href="#cite_ref-44">↑</a></span> <span class="reference-text">Yuan F, Qingqing L, Wenyi G, Xinghuai S. Profile of pediatric glaucoma patients in Shanghai Eye, Ear, Nose and Throat Hospital. <i>Chinese Medical Journal</i> 2014; <b>127</b>(8): 1429-33.</span>
</li>
<li id="cite_note-45"><span class="mw-cite-backlink"><a href="#cite_ref-45">↑</a></span> <span class="reference-text">Ben-Zion I, Tomkins O, Moore DB, Helveston EM. Surgical results in the management of advanced primary congenital glaucoma in a rural pediatric population. <i>Ophthalmology</i> 2011; <b>118</b>(2): 231-5. e1.</span>
</li>
<li id="cite_note-46"><span class="mw-cite-backlink"><a href="#cite_ref-46">↑</a></span> <span class="reference-text">Zagora SL, Funnell CL, Martin FJ, et al. Primary congenital glaucoma outcomes: lessons from 23 years of follow-up. <i>American journal of ophthalmology</i> 2015; <b>159</b>(4): 788-96. e2.</span>
</li>
<li id="cite_note-47"><span class="mw-cite-backlink"><a href="#cite_ref-47">↑</a></span> <span class="reference-text">Alsheikheh A, Klink J, Klink T, Steffen H, Grehn F. Long-term results of surgery in childhood glaucoma. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> 2007; <b>245</b>(2): 195-203.</span>
</li>
<li id="cite_note-48"><span class="mw-cite-backlink"><a href="#cite_ref-48">↑</a></span> <span class="reference-text">Haargaard B, Ritz C, Oudin A, et al. Risk of glaucoma after pediatric cataract surgery. <i>Investigative ophthalmology &amp; visual science</i> 2008; <b>49</b>(5): 1791-6.</span>
</li>
<li id="cite_note-49"><span class="mw-cite-backlink"><a href="#cite_ref-49">↑</a></span> <span class="reference-text">Lawrence MG, Kramarevsky NY, Christiansen SP, Wright MM, Young TL, Summers CG. Glaucoma following cataract surgery in children: surgically modifiable risk factors. <i>Transactions of the American Ophthalmological Society</i> 2005; <b>103</b>: 46.</span>
</li>
<li id="cite_note-50"><span class="mw-cite-backlink"><a href="#cite_ref-50">↑</a></span> <span class="reference-text">Magnusson G, Abrahamsson M, Sjöstrand J. Glaucoma following congenital cataract surgery: an 18‐year longitudinal follow‐up. <i>Acta ophthalmologica Scandinavica</i> 2000; <b>78</b>(1): 65-70.</span>
</li>
<li id="cite_note-51"><span class="mw-cite-backlink"><a href="#cite_ref-51">↑</a></span> <span class="reference-text">Swamy BN, Billson F, Martin F, et al. Secondary glaucoma after paediatric cataract surgery. <i>British journal of ophthalmology</i> 2007; <b>91</b>(12): 1627-30.</span>
</li>
<li id="cite_note-52"><span class="mw-cite-backlink"><a href="#cite_ref-52">↑</a></span> <span class="reference-text">Paudyal I, Thapa SS, Paudyal G, et al. Glaucoma at a tertiary referral eye hospital in Nepal. <i>Nepal Journal of Ophthalmology</i> 2011; <b>3</b>(2): 123-7.</span>
</li>
<li id="cite_note-53"><span class="mw-cite-backlink"><a href="#cite_ref-53">↑</a></span> <span class="reference-text">Ashaye A, Ashaolu O, Komolafe O, et al. Prevalence and types of glaucoma among an indigenous African population in southwestern Nigeria. <i>Investigative ophthalmology &amp; visual science</i> 2013; <b>54</b>(12): 7410-6.</span>
</li>
<li id="cite_note-54"><span class="mw-cite-backlink"><a href="#cite_ref-54">↑</a></span> <span class="reference-text">Asuquo IM, Busuyi HM, Umar KO. The dangers of couching in southwest Nigeria. <i>The Malaysian journal of medical sciences: MJMS</i> 2014; <b>21</b>(5): 60.</span>
</li>
<li id="cite_note-55"><span class="mw-cite-backlink"><a href="#cite_ref-55">↑</a></span> <span class="reference-text">Meda N, Bognounou V, Seni E, Daboue A, Sanfo O. Cataract in Burkina Faso: factors of choice between modern and traditional surgical procedures. <i>Medecine tropicale: revue du Corps de sante colonial</i> 2005; <b>65</b>(5): 473.</span>
</li>
<li id="cite_note-56"><span class="mw-cite-backlink"><a href="#cite_ref-56">↑</a></span> <span class="reference-text">Omoti A. Complications of traditional couching in a Nigerian local population. <i>West African journal of medicine</i> 2005; <b>24</b>(1): 7-9.</span>
</li>
<li id="cite_note-57"><span class="mw-cite-backlink"><a href="#cite_ref-57">↑</a></span> <span class="reference-text">Schémann J-F, Bakayoko S, Coulibaly S. Traditional couching is not an effective alternative procedure for cataract surgery in Mali. <i>Ophthalmic epidemiology</i> 2000; <b>7</b>(4): 271-83.</span>
</li>
<li id="cite_note-58"><span class="mw-cite-backlink"><a href="#cite_ref-58">↑</a></span> <span class="reference-text">Ashaye A, Adeoti C. Neovascular glaucoma in a Nigerian African population. <i>East African medical journal</i> 2006; <b>83</b>(10): 559-64.</span>
</li>
<li id="cite_note-59"><span class="mw-cite-backlink"><a href="#cite_ref-59">↑</a></span> <span class="reference-text">Brown GC, Magargal LE, Schachat A, Shah H. Neovascular glaucoma: etiologic considerations. <i>Ophthalmology</i> 1984; <b>91</b>(4): 315-20.</span>
</li>
<li id="cite_note-60"><span class="mw-cite-backlink"><a href="#cite_ref-60">↑</a></span> <span class="reference-text">Sayin N, Kara N, Pekel G. Ocular complications of diabetes mellitus. <i>World journal of diabetes</i> 2015; <b>6</b>(1): 92.</span>
</li>
<li id="cite_note-61"><span class="mw-cite-backlink"><a href="#cite_ref-61">↑</a></span> <span class="reference-text">Al-Shamsi HN, Dueker DK, Nowilaty SR, Al-Shahwan SA. Neovascular glaucoma at king khaled eye specialist hospital–etiologic considerations. <i>Middle East African Journal of Ophthalmology</i> 2009; <b>16</b>(1): 15.</span>
</li>
<li id="cite_note-62"><span class="mw-cite-backlink"><a href="#cite_ref-62">↑</a></span> <span class="reference-text">Gadia R, Sihota R, Dada T, Gupta V. Current profile of secondary glaucomas. <i>Indian journal of ophthalmology</i> 2008; <b>56</b>(4): 285.</span>
</li>
<li id="cite_note-63"><span class="mw-cite-backlink"><a href="#cite_ref-63">↑</a></span> <span class="reference-text">Tenkir A, Solomon B, Deribew A. Glaucoma subtypes in Ethiopian clinic patients. <i>Journal of glaucoma</i> 2013; <b>22</b>(2): 110-6.</span>
</li>
<li id="cite_note-64"><span class="mw-cite-backlink"><a href="#cite_ref-64">↑</a></span> <span class="reference-text">Vijaya L, Asokan R, Panday M, et al. The prevalence of pseudoexfoliation and the long-term changes in eyes with pseudoexfoliation in a South Indian population. <i>Journal of Glaucoma</i> 2016; <b>25</b>(6): e596-e602.</span>
</li>
<li id="cite_note-:18-65"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:18_65-0">65.0</a></sup> <sup><a href="#cite_ref-:18_65-1">65.1</a></sup></span> <span class="reference-text">Kuper H, Polack S, Mathenge W, et al. Does cataract surgery alleviate poverty? Evidence from a multi-centre intervention study conducted in Kenya, the Philippines and Bangladesh. <i>PloS one</i> 2010; <b>5</b>(11): e15431.</span>
</li>
<li id="cite_note-66"><span class="mw-cite-backlink"><a href="#cite_ref-66">↑</a></span> <span class="reference-text">Zimmer Z. Poverty, wealth inequality and health among older adults in rural Cambodia. <i>Social Science &amp; Medicine</i> 2008; <b>66</b>(1): 57-71.</span>
</li>
<li id="cite_note-67"><span class="mw-cite-backlink"><a href="#cite_ref-67">↑</a></span> <span class="reference-text">Gupta V, Srinivasan G, Mei S, Gazzard G, Sihota R, Kapoor K. Utility values among glaucoma patients: an impact on the quality of life. <i>British journal of ophthalmology</i> 2005; <b>89</b>(10): 1241-4.</span>
</li>
<li id="cite_note-68"><span class="mw-cite-backlink"><a href="#cite_ref-68">↑</a></span> <span class="reference-text">Jampel HD, Schwartz A, Pollack I, Abrams D, Weiss H, Miller R. Glaucoma patients' assessment of their visual function and quality of life. <i>Journal of glaucoma</i> 2002; <b>11</b>(2): 154-63.</span>
</li>
<li id="cite_note-69"><span class="mw-cite-backlink"><a href="#cite_ref-69">↑</a></span> <span class="reference-text">Gothwal VK, Bagga DK, Rao HL, et al. Is utility-based quality of life in adults affected by glaucoma? <i>Investigative Ophthalmology &amp; Visual Science</i> 2014; <b>55</b>(3): 1361-9.</span>
</li>
<li id="cite_note-70"><span class="mw-cite-backlink"><a href="#cite_ref-70">↑</a></span> <span class="reference-text">Guedes RAP, Guedes VMP, Freitas SM, Chaoubah A. Utility values for glaucoma in Brazil and their correlation with visual function. <i>Clinical Ophthalmology (Auckland, NZ)</i> 2014; <b>8</b>: 529.</span>
</li>
<li id="cite_note-71"><span class="mw-cite-backlink"><a href="#cite_ref-71">↑</a></span> <span class="reference-text">Zhou C, Qian S, Wu P, Qiu C. Quality of life of glaucoma patients in China: sociodemographic, clinical, and psychological correlates—a cross-sectional study. <i>Quality of Life Research</i> 2014; <b>23</b>(3): 999-1008.</span>
</li>
<li id="cite_note-72"><span class="mw-cite-backlink"><a href="#cite_ref-72">↑</a></span> <span class="reference-text">Adelman RD, Tmanova LL, Delgado D, Dion S, Lachs MS. Caregiver burden: a clinical review. <i>Jama</i> 2014; <b>311</b>(10): 1052-60.</span>
</li>
<li id="cite_note-73"><span class="mw-cite-backlink"><a href="#cite_ref-73">↑</a></span> <span class="reference-text">Braich PS, Lal V, Hollands S, Almeida DR. Burden and depression in the caregivers of blind patients in India. <i>Ophthalmology</i> 2012; <b>119</b>(2): 221-6.</span>
</li>
<li id="cite_note-74"><span class="mw-cite-backlink"><a href="#cite_ref-74">↑</a></span> <span class="reference-text">Köberlein J, Beifus K, Schaffert C, Finger RP. The economic burden of visual impairment and blindness: a systematic review. <i>BMJ open</i> 2013; <b>3</b>(11).</span>
</li>
<li id="cite_note-75"><span class="mw-cite-backlink"><a href="#cite_ref-75">↑</a></span> <span class="reference-text">Wittenborn JS, Rein DB. The cost-effectiveness of glaucoma interventions in Barbados and Ghana. <i>Optometry and vision science: official publication of the American Academy of Optometry</i> 2011; <b>88</b>(1): 155.</span>
</li>
<li id="cite_note-76"><span class="mw-cite-backlink"><a href="#cite_ref-76">↑</a></span> <span class="reference-text">Hernández R, Rabindranath K, Fraser C, Vale L, Blanco AA, Burr JM. Screening for open angle glaucoma: systematic review of cost-effectiveness studies. <i>Journal of glaucoma</i> 2008; <b>17</b>(3): 159-68.</span>
</li>
<li id="cite_note-:19-77"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:19_77-0">77.0</a></sup> <sup><a href="#cite_ref-:19_77-1">77.1</a></sup> <sup><a href="#cite_ref-:19_77-2">77.2</a></sup></span> <span class="reference-text">Organization WH. World report on vision. 2019. 2020.</span>
</li>
<li id="cite_note-:20-78"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:20_78-0">78.0</a></sup> <sup><a href="#cite_ref-:20_78-1">78.1</a></sup> <sup><a href="#cite_ref-:20_78-2">78.2</a></sup> <sup><a href="#cite_ref-:20_78-3">78.3</a></sup> <sup><a href="#cite_ref-:20_78-4">78.4</a></sup></span> <span class="reference-text">Rani PK, Nangia V, Murthy KR, Khanna RC, Das T. Community care for diabetic retinopathy and glaucoma in India: A panel discussion. <i>Indian Journal of Ophthalmology</i> 2018; <b>66</b>(7): 916.</span>
</li>
<li id="cite_note-:21-79"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:21_79-0">79.0</a></sup> <sup><a href="#cite_ref-:21_79-1">79.1</a></sup></span> <span class="reference-text">Cook C. Glaucoma in Africa: size of the problem and possible solutions. <i>Journal of glaucoma</i> 2009; <b>18</b>(2): 124-8.</span>
</li>
<li id="cite_note-80"><span class="mw-cite-backlink"><a href="#cite_ref-80">↑</a></span> <span class="reference-text">Gyasi M, Amoako W, Adjuik M. Presentation patterns of primary open angle glaucomas in north eastern ghana. <i>Ghana medical journal</i> 2010; <b>44</b>(1).</span>
</li>
<li id="cite_note-:22-81"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:22_81-0">81.0</a></sup> <sup><a href="#cite_ref-:22_81-1">81.1</a></sup></span> <span class="reference-text">Abdull MM, Gilbert CC, Evans J. Primary open angle glaucoma in northern Nigeria: stage at presentation and acceptance of treatment. <i>BMC ophthalmology</i> 2015; <b>15</b>(1): 111.</span>
</li>
<li id="cite_note-82"><span class="mw-cite-backlink"><a href="#cite_ref-82">↑</a></span> <span class="reference-text">Kyari F, Nolan W, Gilbert C. Ophthalmologists' practice patterns and challenges in achieving optimal management for glaucoma in Nigeria: results from a nationwide survey. <i>BMJ open</i> 2016; <b>6</b>(10): e012230.</span>
</li>
<li id="cite_note-:23-83"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:23_83-0">83.0</a></sup> <sup><a href="#cite_ref-:23_83-1">83.1</a></sup></span> <span class="reference-text">Adekoya B, Adepoju F, Moshood K, Balarabe A. Challenges in the management of glaucoma in a developing country; a qualitative study of providers' perspectives. <i>Nigerian Journal of Medicine</i> 2015; <b>24</b>(4): 315-22.</span>
</li>
<li id="cite_note-:24-84"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:24_84-0">84.0</a></sup> <sup><a href="#cite_ref-:24_84-1">84.1</a></sup> <sup><a href="#cite_ref-:24_84-2">84.2</a></sup></span> <span class="reference-text">Delgado MF, Abdelrahman AM, Terahi M, et al. Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement. <i>ClinicoEconomics and Outcomes Research: CEOR</i> 2019; <b>11</b>: 591.</span>
</li>
<li id="cite_note-85"><span class="mw-cite-backlink"><a href="#cite_ref-85">↑</a></span> <span class="reference-text">Killeen OJ, Pillai MR, Udayakumar B, et al. Understanding Barriers to Glaucoma Treatment Adherence among Participants in South India. <i>Ophthalmic Epidemiology</i> 2020; <b>27</b>(3): 200-8.</span>
</li>
<li id="cite_note-86"><span class="mw-cite-backlink"><a href="#cite_ref-86">↑</a></span> <span class="reference-text">Nayak B, Gupta S, Kumar G, Dada T, Gupta V, Sihota R. Socioeconomics of long-term glaucoma therapy in India. <i>Indian Journal of Ophthalmology</i> 2015; <b>63</b>(1): 20.</span>
</li>
<li id="cite_note-87"><span class="mw-cite-backlink"><a href="#cite_ref-87">↑</a></span> <span class="reference-text">Tamrat L, Gessesse GW, Gelaw Y. Adherence to topical glaucoma medications in Ethiopian patients. <i>Middle East African journal of ophthalmology</i> 2015; <b>22</b>(1): 59.</span>
</li>
<li id="cite_note-:25-88"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:25_88-0">88.0</a></sup> <sup><a href="#cite_ref-:25_88-1">88.1</a></sup></span> <span class="reference-text">Thomas R. Glaucoma in developing countries. <i>Indian journal of ophthalmology</i> 2012; <b>60</b>(5): 446.</span>
</li>
<li id="cite_note-:26-89"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:26_89-0">89.0</a></sup> <sup><a href="#cite_ref-:26_89-1">89.1</a></sup></span> <span class="reference-text">Ting NS, Yim JFL, Ng JY. Different strategies and cost-effectiveness in the treatment of primary open angle glaucoma. <i>ClinicoEconomics and outcomes research: CEOR</i> 2014; <b>6</b>: 523.</span>
</li>
<li id="cite_note-:27-90"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:27_90-0">90.0</a></sup> <sup><a href="#cite_ref-:27_90-1">90.1</a></sup> <sup><a href="#cite_ref-:27_90-2">90.2</a></sup></span> <span class="reference-text">Anand A, Negi S, Khokhar S, et al. Role of early trabeculectomy in primary open-angle glaucoma in the developing world. <i>Eye</i> 2007; <b>21</b>(1): 40-5.</span>
</li>
<li id="cite_note-:28-91"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:28_91-0">91.0</a></sup> <sup><a href="#cite_ref-:28_91-1">91.1</a></sup> <sup><a href="#cite_ref-:28_91-2">91.2</a></sup></span> <span class="reference-text">Quigley HA, Buhrmann RR, West SK, Isseme I, Scudder M, Oliva MS. Long term results of glaucoma surgery among participants in an east African population survey. <i>British Journal of Ophthalmology</i> 2000; <b>84</b>(8): 860-4.</span>
</li>
<li id="cite_note-:29-92"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:29_92-0">92.0</a></sup> <sup><a href="#cite_ref-:29_92-1">92.1</a></sup></span> <span class="reference-text">Adekoya BJ, Onakoya AO, Shah SP, Adepoju FG. Surgical output and clinic burden of glaucoma in Lagos, Nigeria. <i>Journal of glaucoma</i> 2014; <b>23</b>(1): 41-5.</span>
</li>
<li id="cite_note-:30-93"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:30_93-0">93.0</a></sup> <sup><a href="#cite_ref-:30_93-1">93.1</a></sup></span> <span class="reference-text">Dhalla K, Cousens S, Bowman R, Wood M, Murdoch I. Is beta radiation better than 5 flurouracil as an adjunct for trabeculectomy surgery when combined with cataract surgery? A randomised controlled trial. <i>PloS one</i> 2016; <b>11</b>(9): e0161674.</span>
</li>
<li id="cite_note-94"><span class="mw-cite-backlink"><a href="#cite_ref-94">↑</a></span> <span class="reference-text">Ramchandani M. Glaucoma in the developing world. British Medical Journal Publishing Group; 2006.</span>
</li>
<li id="cite_note-95"><span class="mw-cite-backlink"><a href="#cite_ref-95">↑</a></span> <span class="reference-text">Cabourne E, Clarke JC, Schlottmann PG, Evans JR. Mitomycin C versus 5‐Fluorouracil for wound healing in glaucoma surgery. <i>Cochrane Database of Systematic Reviews</i> 2015; (11).</span>
</li>
<li id="cite_note-:31-96"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:31_96-0">96.0</a></sup> <sup><a href="#cite_ref-:31_96-1">96.1</a></sup></span> <span class="reference-text">Gedde SJ, Herndon LW, Brandt JD, et al. Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. <i>American journal of ophthalmology</i> 2012; <b>153</b>(5): 804-14. e1.</span>
</li>
<li id="cite_note-97"><span class="mw-cite-backlink"><a href="#cite_ref-97">↑</a></span> <span class="reference-text">Duman F, Faria B, Rutnin N, et al. Comparison of 3 different releasable suture techniques in trabeculectomy. <i>European journal of ophthalmology</i> 2016; <b>26</b>(4): 307-14.</span>
</li>
<li id="cite_note-98"><span class="mw-cite-backlink"><a href="#cite_ref-98">↑</a></span> <span class="reference-text">Venkatesh R, Sengupta S, Robin AL. Mitomycin C–Augmented Trabeculectomy Combined With Single-Site Manual Small-Incision Cataract Surgery Through a Tunnel Flap Technique. <i>The Asia-Pacific Journal of Ophthalmology</i> 2012; <b>1</b>(3): 142-6.</span>
</li>
<li id="cite_note-99"><span class="mw-cite-backlink"><a href="#cite_ref-99">↑</a></span> <span class="reference-text">Broadway D, Grierson I, Hitchings R. Racial differences in the results of glaucoma filtration surgery: are racial differences in the conjunctival cell profile important? <i>British Journal of Ophthalmology</i> 1994; <b>78</b>(6): 466-75.</span>
</li>
<li id="cite_note-100"><span class="mw-cite-backlink"><a href="#cite_ref-100">↑</a></span> <span class="reference-text">Investigators A. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results. <i>Ophthalmology</i> 2004; <b>111</b>(4): 651-64.</span>
</li>
<li id="cite_note-101"><span class="mw-cite-backlink"><a href="#cite_ref-101">↑</a></span> <span class="reference-text">Budenz DL, Barton K, Feuer WJ, et al. Treatment outcomes in the Ahmed Baerveldt Comparison Study after 1 year of follow-up. <i>Ophthalmology</i> 2011; <b>118</b>(3): 443-52.</span>
</li>
<li id="cite_note-102"><span class="mw-cite-backlink"><a href="#cite_ref-102">↑</a></span> <span class="reference-text">Christakis PG, Kalenak JW, Zurakowski D, et al. The Ahmed Versus Baerveldt study: one-year treatment outcomes. <i>Ophthalmology</i> 2011; <b>118</b>(11): 2180-9.</span>
</li>
<li id="cite_note-103"><span class="mw-cite-backlink"><a href="#cite_ref-103">↑</a></span> <span class="reference-text">Kiage D, Gradin D, Gichuhi S, Damji K. Ahmed glaucoma valve implant: experience in East Africa. <i>Middle East African Journal of Ophthalmology</i> 2009; <b>16</b>(3): 151.</span>
</li>
<li id="cite_note-104"><span class="mw-cite-backlink"><a href="#cite_ref-104">↑</a></span> <span class="reference-text">Giorgis A. Initial clinical experience of tube-shunt surgery in Ethiopian patients with refractory glaucoma. <i>Ethiop Med J</i> 2012; <b>50</b>(2): 159-65.</span>
</li>
<li id="cite_note-105"><span class="mw-cite-backlink"><a href="#cite_ref-105">↑</a></span> <span class="reference-text">Aminlari AE, Scott IU, Aref AA. Glaucoma drainage implant surgery–An evidence-based update with relevance to Sub-Saharan Africa. <i>Middle East African journal of ophthalmology</i> 2013; <b>20</b>(2): 126.</span>
</li>
<li id="cite_note-106"><span class="mw-cite-backlink"><a href="#cite_ref-106">↑</a></span> <span class="reference-text">Haripriya A, Chang DF, Ravindran RD. Endophthalmitis reduction with intracameral moxifloxacin in eyes with and without surgical complications: Results from 2 million consecutive cataract surgeries. <i>J Cataract Refract Surg</i> 2019; <b>45</b>(9): 1226-33.</span>
</li>
<li id="cite_note-107"><span class="mw-cite-backlink"><a href="#cite_ref-107">↑</a></span> <span class="reference-text">Mitchell W, Tom L, Durai I, et al. The Effectiveness of Intracameral Moxifloxacin Endophthalmitis Prophylaxis for&#160;Trabeculectomy. <i>Ophthalmol Glaucoma</i> 2020.</span>
</li>
<li id="cite_note-108"><span class="mw-cite-backlink"><a href="#cite_ref-108">↑</a></span> <span class="reference-text">Tham CC, Kwong YY, Leung DY, et al. Phacoemulsification versus combined phacotrabeculectomy in medically controlled chronic angle closure glaucoma with cataract. <i>Ophthalmology</i> 2008; <b>115</b>(12): 2167-73. e2.</span>
</li>
<li id="cite_note-109"><span class="mw-cite-backlink"><a href="#cite_ref-109">↑</a></span> <span class="reference-text">Tham CC, Kwong YY, Leung DY, et al. Phacoemulsification versus combined phacotrabeculectomy in medically uncontrolled chronic angle closure glaucoma with cataracts. <i>Ophthalmology</i> 2009; <b>116</b>(4): 725-31. e3.</span>
</li>
<li id="cite_note-110"><span class="mw-cite-backlink"><a href="#cite_ref-110">↑</a></span> <span class="reference-text">Bechrakis N, Dimmer A. Rhegmatogene Netzhautablösung. <i>Der Ophthalmologe</i> 2018; <b>115</b>(2): 163-78.</span>
</li>
<li id="cite_note-111"><span class="mw-cite-backlink"><a href="#cite_ref-111">↑</a></span> <span class="reference-text">Azuara-Blanco A, Burr J, Ramsay C, et al. Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial. <i>The Lancet</i> 2016; <b>388</b>(10052): 1389-97.</span>
</li>
<li id="cite_note-112"><span class="mw-cite-backlink"><a href="#cite_ref-112">↑</a></span> <span class="reference-text">Tham CC, Kwong YY, Baig N, Leung DY, Li FC, Lam DS. Phacoemulsification versus trabeculectomy in medically uncontrolled chronic angle-closure glaucoma without cataract. <i>Ophthalmology</i> 2013; <b>120</b>(1): 62-7.</span>
</li>
<li id="cite_note-113"><span class="mw-cite-backlink"><a href="#cite_ref-113">↑</a></span> <span class="reference-text">Kiddee W, Tantisarasart T, Wangsupadilok B. Neovascular glaucoma: a retrospective review of 5-year experience in Songklanagarind Hospital. <i>J Med Assoc Thai</i> 2012; <b>95</b>(Suppl 4): S36-S42.</span>
</li>
<li id="cite_note-114"><span class="mw-cite-backlink"><a href="#cite_ref-114">↑</a></span> <span class="reference-text">Realini T. Selective laser trabeculoplasty for the management of open-angle glaucoma in St. Lucia. <i>JAMA ophthalmology</i> 2013; <b>131</b>(3): 321-7.</span>
</li>
<li id="cite_note-115"><span class="mw-cite-backlink"><a href="#cite_ref-115">↑</a></span> <span class="reference-text">Lee JW, Liu CC, Chan JC, Lai JS. Predictors of success in selective laser trabeculoplasty for Chinese open-angle glaucoma. <i>Journal of glaucoma</i> 2014; <b>23</b>(5): 321-5.</span>
</li>
<li id="cite_note-116"><span class="mw-cite-backlink"><a href="#cite_ref-116">↑</a></span> <span class="reference-text">Realini T, Olawoye O, Kizor-Akaraiwe N, Manji S, Sit A. The rationale for selective laser trabeculoplasty in Africa. <i>The Asia-Pacific Journal of Ophthalmology</i> 2018; <b>7</b>(6): 387-93.</span>
</li>
<li id="cite_note-117"><span class="mw-cite-backlink"><a href="#cite_ref-117">↑</a></span> <span class="reference-text">Gupta V, Agarwal HC. Contact trans-scleral laser cyclophotocoagulation treatment for refractory glaucomas in the Indian population. <i>Indian Journal of Ophthalmology</i> 2000; <b>48</b>(4): 295.</span>
</li>
<li id="cite_note-118"><span class="mw-cite-backlink"><a href="#cite_ref-118">↑</a></span> <span class="reference-text">Schwering MS, Kayange P, Klauss V, Kalua K, Spitzer MS. Low-dose transscleral diode laser cyclophotocoagulation (TSCPC) as a potential single treatment for primary open-angle glaucoma (POAG) in Malawi? <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> 2013; <b>251</b>(10): 2389-93.</span>
</li>
<li id="cite_note-119"><span class="mw-cite-backlink"><a href="#cite_ref-119">↑</a></span> <span class="reference-text">Mavrakanas N, Dhalla K, Kapesa I, Alibhai A, Murdoch I. Diode laser transscleral cyclophotocoagulation for the treatment of glaucoma in East Africa. <i>Eye</i> 2013; <b>27</b>(3): 453-4.</span>
</li>
<li id="cite_note-120"><span class="mw-cite-backlink"><a href="#cite_ref-120">↑</a></span> <span class="reference-text">Preußner P-R, Ngounou F, Kouogan G. Controlled cyclophotocoagulation with the 940 nm laser for primary open angle glaucoma in African eyes. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> 2010; <b>248</b>(10): 1473-9.</span>
</li>
<li id="cite_note-121"><span class="mw-cite-backlink"><a href="#cite_ref-121">↑</a></span> <span class="reference-text">Johnstone MA, Shaozhen S, Padilla S, et al. Microscope Real-time Video (MRTV), High-resolution OCT (HR-OCT) &amp; Histopathology (HP) to Assess How Transcleral Micropulse Laser (TML) Affects the Sclera, Ciliary Body (CB), Muscle (CM), Secretory Epithelium (CBSE), Suprachoroidal Space (SCS) &amp; Aqueous Outflow System. <i>Investigative Ophthalmology &amp; Visual Science</i> 2019; <b>60</b>(9): 2825-.</span>
</li>
<li id="cite_note-122"><span class="mw-cite-backlink"><a href="#cite_ref-122">↑</a></span> <span class="reference-text">The Commonwealth Fund. What Impact Has COVID-19 Had on Outpatient Visits?. https://www.commonwealthfund.org/publications/2020/apr/impact-covid-19-outpatient-visits. Accessed 2 May 2020.</span>
</li>
<li id="cite_note-123"><span class="mw-cite-backlink"><a href="#cite_ref-123">↑</a></span> <span class="reference-text">Nair AG, Gandhi RA, Natarajan S. Effect of COVID-19 related lockdown on ophthalmic practice and patient care in India: Results of a survey. <i>Indian J Ophthalmol</i> 2020; <b>68</b>(5): 725-30.</span>
</li>
<li id="cite_note-:32-124"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:32_124-0">124.0</a></sup> <sup><a href="#cite_ref-:32_124-1">124.1</a></sup></span> <span class="reference-text">Ohannessian R, Duong TA, Odone A. Global telemedicine implementation and integration within health systems to fight the COVID-19 pandemic: a call to action. <i>JMIR Public Health and Surveillance</i> 2020; <b>6</b>(2): e18810.</span>
</li>
<li id="cite_note-:33-125"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:33_125-0">125.0</a></sup> <sup><a href="#cite_ref-:33_125-1">125.1</a></sup></span> <span class="reference-text">Mann DM, Chen J, Chunara R, Testa PA, Nov O. COVID-19 transforms health care through telemedicine: evidence from the field. <i>Journal of the American Medical Informatics Association</i> 2020.</span>
</li>
<li id="cite_note-:34-126"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:34_126-0">126.0</a></sup> <sup><a href="#cite_ref-:34_126-1">126.1</a></sup></span> <span class="reference-text">Hollander JE, Carr BG. Virtually Perfect? Telemedicine for Covid-19. <i>N Engl J Med</i> 2020; <b>382</b>(18): 1679-81.</span>
</li>
<li id="cite_note-:35-127"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:35_127-0">127.0</a></sup> <sup><a href="#cite_ref-:35_127-1">127.1</a></sup></span> <span class="reference-text">Chauhan V, Galwankar S, Arquilla B, et al. Novel coronavirus (COVID-19): Leveraging telemedicine to optimize care while minimizing exposures and viral transmission. <i>Journal of Emergencies, Trauma, and Shock</i> 2020; <b>13</b>(1): 20.</span>
</li>
<li id="cite_note-:36-128"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:36_128-0">128.0</a></sup> <sup><a href="#cite_ref-:36_128-1">128.1</a></sup></span> <span class="reference-text">Romano MR, Montericcio A, Montalbano C, et al. Facing COVID-19 in Ophthalmology Department. <i>Curr Eye Res</i> 2020: 1-6.</span>
</li>
<li id="cite_note-129"><span class="mw-cite-backlink"><a href="#cite_ref-129">↑</a></span> <span class="reference-text">Kalra G, Williams AM, Commiskey PW, et al. Incorporating Video Visits into Ophthalmology Practice: A Retrospective Analysis and Patient Survey to Assess Initial Experiences and Patient Acceptability at an Academic Eye Center. <i>Ophthalmology and Therapy</i> 2020: 1-14.</span>
</li>
<li id="cite_note-130"><span class="mw-cite-backlink"><a href="#cite_ref-130">↑</a></span> <span class="reference-text">Williams AM, Kalra G, Commiskey PW, et al. Ophthalmology practice during the coronavirus disease 2019 pandemic: The University of Pittsburgh Experience in promoting clinic safety and embracing video visits. <i>Ophthalmology and therapy</i> 2020: 1.</span>
</li>
<li id="cite_note-:37-131"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:37_131-0">131.0</a></sup> <sup><a href="#cite_ref-:37_131-1">131.1</a></sup> <sup><a href="#cite_ref-:37_131-2">131.2</a></sup></span> <span class="reference-text">Mohammadpour M, Heidari Z, Mirghorbani M, Hashemi H. Smartphones, tele-ophthalmology, and VISION 2020. <i>International journal of ophthalmology</i> 2017; <b>10</b>(12): 1909.</span>
</li>
<li id="cite_note-:38-132"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:38_132-0">132.0</a></sup> <sup><a href="#cite_ref-:38_132-1">132.1</a></sup></span> <span class="reference-text">Stanzel B, Meyer C. Smartphones in ophthalmology: Relief or toys for physicians? <i>Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft</i> 2012; <b>109</b>(1): 8-20.</span>
</li>
<li id="cite_note-:39-133"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:39_133-0">133.0</a></sup> <sup><a href="#cite_ref-:39_133-1">133.1</a></sup></span> <span class="reference-text">Chhablani J, Kaja S, Shah VA. Smartphones in ophthalmology. <i>Indian journal of ophthalmology</i> 2012; <b>60</b>(2): 127.</span>
</li>
<li id="cite_note-:40-134"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:40_134-0">134.0</a></sup> <sup><a href="#cite_ref-:40_134-1">134.1</a></sup></span> <span class="reference-text">Lord RK, Shah VA, San Filippo AN, Krishna R. Novel uses of smartphones in ophthalmology. <i>Ophthalmology</i> 2010; <b>117</b>(6): 1274-. e3.</span>
</li>
<li id="cite_note-:41-135"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:41_135-0">135.0</a></sup> <sup><a href="#cite_ref-:41_135-1">135.1</a></sup></span> <span class="reference-text">Labiris G, Panagiotopoulou E-K, Kozobolis VP. A systematic review of teleophthalmological studies in Europe. <i>International journal of ophthalmology</i> 2018; <b>11</b>(2): 314.</span>
</li>
<li id="cite_note-:42-136"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:42_136-0">136.0</a></sup> <sup><a href="#cite_ref-:42_136-1">136.1</a></sup></span> <span class="reference-text">Sreelatha OK, Ramesh SV. Teleophthalmology: improving patient outcomes? <i>Clinical ophthalmology (Auckland, NZ)</i> 2016; <b>10</b>: 285.</span>
</li>
<li id="cite_note-:43-137"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:43_137-0">137.0</a></sup> <sup><a href="#cite_ref-:43_137-1">137.1</a></sup></span> <span class="reference-text">Zimmer-Galler IE, Zeimer R. Telemedicine in Diabetic Retinopathy Screening. <i>International Ophthalmology Clinics</i> 2009; <b>49</b>(2): 75-86.</span>
</li>
<li id="cite_note-:44-138"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:44_138-0">138.0</a></sup> <sup><a href="#cite_ref-:44_138-1">138.1</a></sup></span> <span class="reference-text">Bar-Sela SM, Glovinsky Y. A feasibility study of an Internet-based telemedicine system for consultation in an ophthalmic emergency room. <i>J Telemed Telecare</i> 2007; <b>13</b>(3): 119-24.</span>
</li>
<li id="cite_note-:45-139"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:45_139-0">139.0</a></sup> <sup><a href="#cite_ref-:45_139-1">139.1</a></sup></span> <span class="reference-text">Paul PG, Raman R, Rani PK, Deshmukh H, Sharma T. Patient satisfaction levels during teleophthalmology consultation in rural South India. <i>Telemedicine Journal &amp; e-Health</i> 2006; <b>12</b>(5): 571-8.</span>
</li>
<li id="cite_note-:46-140"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:46_140-0">140.0</a></sup> <sup><a href="#cite_ref-:46_140-1">140.1</a></sup></span> <span class="reference-text">Labiris G, Fanariotis M, Christoulakis C, et al. Tele-ophthalmology and conventional ophthalmology using a mobile medical unit in remote Greece. <i>Journal of telemedicine and telecare</i> 2003; <b>9</b>(5): 296-9.</span>
</li>
<li id="cite_note-:47-141"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:47_141-0">141.0</a></sup> <sup><a href="#cite_ref-:47_141-1">141.1</a></sup></span> <span class="reference-text">Fatehi F, Jahedi F, Tay-Kearney M-L, Kanagasingam Y. Teleophthalmology for the elderly population: A review of the literature. <i>International Journal of Medical Informatics</i> 2020: 104089.</span>
</li>
<li id="cite_note-142"><span class="mw-cite-backlink"><a href="#cite_ref-142">↑</a></span> <span class="reference-text">Host BKJ, Turner AW, Muir J. Real-time teleophthalmology video consultation: an analysis of patient satisfaction in rural Western Australia. <i>Clinical and Experimental Optometry</i> 2018; <b>101</b>(1): 129-34.</span>
</li>
<li id="cite_note-143"><span class="mw-cite-backlink"><a href="#cite_ref-143">↑</a></span> <span class="reference-text">Tan IJ, Dobson LP, Bartnik S, Muir J, Turner AW. Real-time teleophthalmology versus face-to-face consultation: A systematic review. <i>J Telemed Telecare</i> 2017; <b>23</b>(7): 629-38.</span>
</li>
<li id="cite_note-144"><span class="mw-cite-backlink"><a href="#cite_ref-144">↑</a></span> <span class="reference-text">Johnson KA, Meyer J, Yazar S, Turner AW. Real-time teleophthalmology in rural Western Australia. <i>The Australian journal of rural health</i> 2015; <b>23</b>(3): 142-9.</span>
</li>
<li id="cite_note-145"><span class="mw-cite-backlink"><a href="#cite_ref-145">↑</a></span> <span class="reference-text">Tan JC, Poh EW, Srinivasan S, Lim TH. A pilot trial of tele-ophthalmology for diagnosis of chronic blurred vision. <i>J Telemed Telecare</i> 2013; <b>19</b>(2): 65-9.</span>
</li>
<li id="cite_note-146"><span class="mw-cite-backlink"><a href="#cite_ref-146">↑</a></span> <span class="reference-text">Choudhari NS, Chandran P, Rao HL, et al. LVPEI Glaucoma Epidemiology and Molecular Genetic Study: teleophthalmology screening for angle-closure disease in an underserved region. <i>Eye</i> 2019: 1-7.</span>
</li>
<li id="cite_note-147"><span class="mw-cite-backlink"><a href="#cite_ref-147">↑</a></span> <span class="reference-text">Odden JL, Khanna CL, Choo CM, et al. Telemedicine in long-term care of glaucoma patients. <i>Journal of Telemedicine and Telecare</i> 2020; <b>26</b>(1-2): 92-9.</span>
</li>
<li id="cite_note-148"><span class="mw-cite-backlink"><a href="#cite_ref-148">↑</a></span> <span class="reference-text">Kotecha A, Baldwin A, Brookes J, Foster PJ. Experiences with developing and implementing a virtual clinic for glaucoma care in an NHS setting. <i>Clin Ophthalmol</i> 2015; <b>9</b>: 1915-23.</span>
</li>
<li id="cite_note-149"><span class="mw-cite-backlink"><a href="#cite_ref-149">↑</a></span> <span class="reference-text">Kim DY, Delori F, Mukai S. Smartphone photography safety. <i>Ophthalmology</i> 2012; <b>119</b>(10): 2200-1.</span>
</li>
<li id="cite_note-150"><span class="mw-cite-backlink"><a href="#cite_ref-150">↑</a></span> <span class="reference-text">Kalra G IP. Kalra G, Ichhpujani P. Smartphone-Based Ocular Photography: Pointers for shortening the learning curve and improving image quality. https://glaucomatoday.com/articles/2019-nov-dec/smartphone-based-ocular-photography. Glaucoma Today. Accessed 5 May 2020.</span>
</li>
<li id="cite_note-151"><span class="mw-cite-backlink"><a href="#cite_ref-151">↑</a></span> <span class="reference-text">Kalra G, Ichhpujani P, Thakur S, Singh RB, Sharma U, Kumar S. A pilot study for smartphone photography to assess bleb morphology and vasculature post-trabeculectomy. <i>International Ophthalmology</i> 2020: 1-8.</span>
</li>
<li id="cite_note-152"><span class="mw-cite-backlink"><a href="#cite_ref-152">↑</a></span> <span class="reference-text">Kumar N, Francesco B, Sharma A. Smartphone-based Gonio-Imaging: A Novel Addition to Glaucoma Screening Tools. <i>Journal of glaucoma</i> 2019; <b>28</b>(9): e149-e50.</span>
</li>
<li id="cite_note-153"><span class="mw-cite-backlink"><a href="#cite_ref-153">↑</a></span> <span class="reference-text">Pujari A, Mukhija R, Chawla R, Phuljhele S, Saxena R, Sharma P. Smartphone-based evaluation of the optic nerve head. <i>Indian journal of ophthalmology</i> 2018; <b>66</b>(11): 1617-8.</span>
</li>
<li id="cite_note-154"><span class="mw-cite-backlink"><a href="#cite_ref-154">↑</a></span> <span class="reference-text">Toy BC, Myung DJ, He L, et al. Smartphone-based dilated fundus photography and near visual acuity testing as inexpensive screening tools to detect referral warranted diabetic eye disease. <i>Retina</i> 2016; <b>36</b>(5): 1000-8.</span>
</li>
<li id="cite_note-155"><span class="mw-cite-backlink"><a href="#cite_ref-155">↑</a></span> <span class="reference-text">Russo A, Morescalchi F, Costagliola C, Delcassi L, Semeraro F. A novel device to exploit the smartphone camera for fundus photography. <i>Journal of ophthalmology</i> 2015; <b>2015</b>.</span>
</li>
<li id="cite_note-156"><span class="mw-cite-backlink"><a href="#cite_ref-156">↑</a></span> <span class="reference-text">Rajalakshmi R, Arulmalar S, Usha M, et al. Validation of smartphone based retinal photography for diabetic retinopathy screening. <i>PloS one</i> 2015; <b>10</b>(9): e0138285.</span>
</li>
<li id="cite_note-157"><span class="mw-cite-backlink"><a href="#cite_ref-157">↑</a></span> <span class="reference-text">Haddock LJ, Kim DY, Mukai S. Simple, inexpensive technique for high-quality smartphone fundus photography in human and animal eyes. <i>Journal of ophthalmology</i> 2013; <b>2013</b>.</span>
</li>
<li id="cite_note-158"><span class="mw-cite-backlink"><a href="#cite_ref-158">↑</a></span> <span class="reference-text">Kumar S, Wang E-H, Pokabla MJ, Noecker RJ. Teleophthalmology assessment of diabetic retinopathy fundus images: smartphone versus standard office computer workstation. <i>TELEMEDICINE and e-HEALTH</i> 2012; <b>18</b>(2): 158-62.</span>
</li>
<li id="cite_note-159"><span class="mw-cite-backlink"><a href="#cite_ref-159">↑</a></span> <span class="reference-text">Russo A, Mapham W, Turano R, et al. Comparison of smartphone ophthalmoscopy with slit-lamp biomicroscopy for grading vertical cup-to-disc ratio. <i>Journal of glaucoma</i> 2016; <b>25</b>(9): e777-e81.</span>
</li>
<li id="cite_note-160"><span class="mw-cite-backlink"><a href="#cite_ref-160">↑</a></span> <span class="reference-text">Rodriguez-Una I, Azuara-Blanco A. New technologies for glaucoma detection. <i>The Asia-Pacific Journal of Ophthalmology</i> 2018; <b>7</b>(6): 394-404.</span>
</li>
<li id="cite_note-161"><span class="mw-cite-backlink"><a href="#cite_ref-161">↑</a></span> <span class="reference-text">Tsapakis S, Papaconstantinou D, Diagourtas A, et al. Home-based visual field test for glaucoma screening comparison with Humphrey perimeter. <i>Clinical Ophthalmology (Auckland, NZ)</i> 2018; <b>12</b>: 2597.</span>
</li>
<li id="cite_note-162"><span class="mw-cite-backlink"><a href="#cite_ref-162">↑</a></span> <span class="reference-text">Mariakakis A, Wang E, Patel S, Wen JC. A smartphone-based system for assessing intraocular pressure. <i>Conference proceedings&#160;:&#160; Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual Conference</i> 2016; <b>2016</b>: 4353-6.</span>
</li>
<li id="cite_note-163"><span class="mw-cite-backlink"><a href="#cite_ref-163">↑</a></span> <span class="reference-text">Rajalakshmi R, Subashini R, Anjana RM, Mohan V. Automated diabetic retinopathy detection in smartphone-based fundus photography using artificial intelligence. <i>Eye</i> 2018; <b>32</b>(6): 1138-44.</span>
</li>
<li id="cite_note-164"><span class="mw-cite-backlink"><a href="#cite_ref-164">↑</a></span> <span class="reference-text">Natarajan S, Jain A, Krishnan R, Rogye A, Sivaprasad S. Diagnostic accuracy of community-based diabetic retinopathy screening with an offline artificial intelligence system on a smartphone. <i>JAMA ophthalmology</i> 2019; <b>137</b>(10): 1182-8.</span>
</li>
<li id="cite_note-165"><span class="mw-cite-backlink"><a href="#cite_ref-165">↑</a></span> <span class="reference-text">Rajalakshmi R. The impact of artificial intelligence in screening for diabetic retinopathy in India. Nature Publishing Group; 2019.</span>
</li>
<li id="cite_note-:48-166"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:48_166-0">166.0</a></sup> <sup><a href="#cite_ref-:48_166-1">166.1</a></sup></span> <span class="reference-text">Ting DSW, Pasquale LR, Peng L, et al. Artificial intelligence and deep learning in ophthalmology. <i>British Journal of Ophthalmology</i> 2019; <b>103</b>(2): 167-75.</span>
</li>
<li id="cite_note-167"><span class="mw-cite-backlink"><a href="#cite_ref-167">↑</a></span> <span class="reference-text">Krishnaiah S, Kovai V, Srinivas M, Shamanna BR, Rao GN, Thomas R. Awareness of glaucoma in the rural population of Southern India. <i>Indian journal of ophthalmology</i> 2005; <b>53</b>(3): 205.</span>
</li>
<li id="cite_note-168"><span class="mw-cite-backlink"><a href="#cite_ref-168">↑</a></span> <span class="reference-text">Sathyamangalam RV, Paul PG, George R, et al. Determinants of glaucoma awareness and knowledge in urban Chennai. <i>Indian journal of ophthalmology</i> 2009; <b>57</b>(5): 355.</span>
</li>
<li id="cite_note-169"><span class="mw-cite-backlink"><a href="#cite_ref-169">↑</a></span> <span class="reference-text">Gasch AT, Wang P, Pasquale LR. Determinants of glaucoma awareness in a general eye clinic. <i>Ophthalmology</i> 2000; <b>107</b>(2): 303-8.</span>
</li>
<li id="cite_note-170"><span class="mw-cite-backlink"><a href="#cite_ref-170">↑</a></span> <span class="reference-text">Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia: the Blue Mountains Eye Study. <i>Ophthalmology</i> 1996; <b>103</b>(10): 1661-9.</span>
</li>
<li id="cite_note-171"><span class="mw-cite-backlink"><a href="#cite_ref-171">↑</a></span> <span class="reference-text">Adekoya BJ, Akinsola FB, Balogun BG, Balogun MM, Ibidapo OO. Patient refusal of glaucoma surgery and associated factors in Lagos, Nigeria. <i>Middle East African journal of ophthalmology</i> 2013; <b>20</b>(2): 168.</span>
</li>
<li id="cite_note-172"><span class="mw-cite-backlink"><a href="#cite_ref-172">↑</a></span> <span class="reference-text">Kong XM, Zhu WQ, Hong JX, Sun XH. Is glaucoma comprehension associated with psychological disturbance and vision-related quality of life for patients with glaucoma? A cross-sectional study. <i>BMJ open</i> 2014; <b>4</b>(5).</span>
</li>
<li id="cite_note-173"><span class="mw-cite-backlink"><a href="#cite_ref-173">↑</a></span> <span class="reference-text">Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. <i>Ophthalmology</i> 2005; <b>112</b>(6): 953-61. e7.</span>
</li>
<li id="cite_note-174"><span class="mw-cite-backlink"><a href="#cite_ref-174">↑</a></span> <span class="reference-text">Craven ER, Walters T, Christie WC, et al. 24-month phase I/II clinical trial of bimatoprost sustained-release implant (Bimatoprost SR) in glaucoma patients. <i>Drugs</i> 2020; <b>80</b>(2): 167-79.</span>
</li>
<li id="cite_note-175"><span class="mw-cite-backlink"><a href="#cite_ref-175">↑</a></span> <span class="reference-text">Resnikoff S, Lansingh VC, Washburn L, et al. Estimated number of ophthalmologists worldwide (International Council of Ophthalmology update): will we meet the needs? <i>British Journal of Ophthalmology</i> 2020; <b>104</b>(4): 588-92.</span>
</li>
<li id="cite_note-176"><span class="mw-cite-backlink"><a href="#cite_ref-176">↑</a></span> <span class="reference-text">Dean W, Gichuhi S, Buchan J, et al. Survey of ophthalmologists-in-training in Eastern, Central and Southern Africa: A regional focus on ophthalmic surgical education. <i>Wellcome open research</i> 2019; <b>4</b>.</span>
</li>
<li id="cite_note-177"><span class="mw-cite-backlink"><a href="#cite_ref-177">↑</a></span> <span class="reference-text">Dean WH, Murray NL, Buchan JC, Golnik K, Kim MJ, Burton MJ. Ophthalmic Simulated Surgical Competency Assessment Rubric for manual small-incision cataract surgery. <i>Journal of Cataract &amp; Refractive Surgery</i> 2019; <b>45</b>(9): 1252-7.</span>
</li>
<li id="cite_note-178"><span class="mw-cite-backlink"><a href="#cite_ref-178">↑</a></span> <span class="reference-text">Orbis Cybersight: A global community of learning sharing and practice. https://cybersight.org/. [Accessed on 7/15/20].</span>
</li>
<li id="cite_note-:49-179"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:49_179-0">179.0</a></sup> <sup><a href="#cite_ref-:49_179-1">179.1</a></sup></span> <span class="reference-text">Du Toit R, Faal HB, Etya’ale D, et al. Evidence for integrating eye health into primary health care in Africa: a health systems strengthening approach. <i>BMC health services research</i> 2013; <b>13</b>(1): 102.</span>
</li>
<li id="cite_note-180"><span class="mw-cite-backlink"><a href="#cite_ref-180">↑</a></span> <span class="reference-text">Mehta P, Shenoy S. Infinite vision: how Aravind became the world's greatest business case for compassion: Berrett-Koehler Publishers; 2011.</span>
</li>
<li id="cite_note-181"><span class="mw-cite-backlink"><a href="#cite_ref-181">↑</a></span> <span class="reference-text">Kappal R, Mehndiratta A, Anandaraj P, Tsanas A. Current impact, future prospects and implications of mobile healthcare in India. <i>Central Asian journal of global health</i> 2014; <b>3</b>(1).</span>
</li>
</ol></div>
<!-- 
NewPP limit report
Cached time: 20230306035154
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] In‐text annotation parser time: 0.027 seconds
CPU time usage: 0.558 seconds
Real time usage: 3.390 seconds
Preprocessor visited node count: 2779/1000000
Post‐expand include size: 7004/2097152 bytes
Template argument size: 2013/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 1/100
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 86339/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  493.891      1 Template:Article
100.00%  493.891      1 -total
 88.82%  438.658      4 Template:Infobox_section
 23.95%  118.303      8 Template:UserLookup
  2.37%   11.728      1 Template:Review_expired
  0.30%    1.468      1 Template:Get_active_contest
  0.18%    0.904      1 Template:Infobox_end
  0.17%    0.848      1 Template:Infobox_begin
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Glaucoma_in_the_Developing_World&amp;oldid=69913">https://eyewiki.org/w/index.php?title=Glaucoma_in_the_Developing_World&amp;oldid=69913</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbpzyxnv5u">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Glaucoma_in_the_Developing_World" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Glaucoma_in_the_Developing_World" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Glaucoma_in_the_Developing_World&amp;oldid=69913" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Glaucoma_in_the_Developing_World&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on June 9, 2021, at 15:56.</div>
					<div>This page has been accessed 52,420 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,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" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0.027},"limitreport":{"cputime":"0.558","walltime":"3.390","ppvisitednodes":{"value":2779,"limit":1000000},"postexpandincludesize":{"value":7004,"limit":2097152},"templateargumentsize":{"value":2013,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":1,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":86339,"limit":5000000},"timingprofile":["100.00%  493.891      1 Template:Article","100.00%  493.891      1 -total"," 88.82%  438.658      4 Template:Infobox_section"," 23.95%  118.303      8 Template:UserLookup","  2.37%   11.728      1 Template:Review_expired","  0.30%    1.468      1 Template:Get_active_contest","  0.18%    0.904      1 Template:Infobox_end","  0.17%    0.848      1 Template:Infobox_begin"]},"cachereport":{"timestamp":"20230306035154","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":7651});});</script></body>
</html>